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Background/aim of the study: Carcinoma-associated fibroblasts (CAFs) represents a 
heterogeneous population of cells and are considered one of the dominant stromal component of 
solid tumours, performing a crucial role in tumour proliferation and metastasis. The main objective 
of this study was to investigate the immunoregulatory features of CAFs isolated from non-small 
cell lung carcinomas  on macrophages and the potential effects of ionizing radiation  on observed 
effects. 
Methods: The study comprise primary cultures of CAFs isolated from freshly resected NSCLC 
(Non Small Lung Cancer) tumours (n=8) and monocyte-derived macrophages prepared from  
peripheral blood of healthy donors.  The experimental settings included both co-cultures and 
incubations of macrophages with CAF-conditioned medium. Moreover, CAF-mediated effects 
were studied in both uncommitted and M1-polarized macrophages. Functional assays to study 
macrophage polarisation included expression of cell surface markers by flow cytometry, production 
of nitric oxide by flow cytometry and secretion of inflammatory cytokines by ELISA. 
Results: All functional assays illustrated that CAFs both in co-culture and by conditioned medium, 
promote changes on uncommitted macrophages (M0) that harmonize with both M1 and M2 
phenotypes. CAFs, both in co-culture and by conditioned medium, could inhibit some of the pro-
inflammatory features of M1 macrophages as demonstrated by strong inhibition of nitric oxide 
production, strong inhibition of proinflammatory cytokines secretion and a reduction of some M1 
surface markers. Importantly, radiation given at high dose (1x18 Gy) or in fractioned regimens (3x6 
Gy) is not able to modify substantially the immunoregulatory features exerted by CAFs over 
macrophages in vitro. Last, protein expression analyses in CAF supernatants show that both 
irradiated and non-irradiated CAFs produced approximately the same levels of cytokines.  
Conclusion: This study display that CAFs-derived soluble factors mediate measurable changes on 
uncomitted macrophages (M0) and down-regulate pro-inflammatory features of M1 polarized 
macrophages, even though the soluble factors accountable for this shift remains unknown. On the 
other hand, this study also illustrates that low dose fractioned radiotherapy and single high dose 
radiotherapy do not curtail the immunosuppressive effect of CAFs. 
 
 





NSCLC: Non-Small Cell Lung Cancer                                                                                   
CT: Computerized Cromatography 
MRI: Magnetic Resonance Imaging 
PET: Positron Emission Tomography 
SABR: Stereotactic Ablative Radiotherapy 
HD-RT: High-Dose Radiotherapy 
CAFs: Carcinoma-Associated Fibroblasts 
BMDC: Bone Marrow Derived Mesenchymal Cells 
TAM: Tumor Associated Macrophages 
ECM: Extracellular Matrix 
EMT: Epithelial Mesenchymal Transdifferentiation 
α-SMA: α-Smooth Muscle Actin 
FAP: Fibroblasts Activation Protein 
FSP-1: Fibroblast-Specific Protein-1 
PDGF: Platelet-Derived Growth Factor 
MMPs: Matrix degrading Metalloproteinase 
uPA: urokinase Plasminogen Activator 
SDF1: Stromal-Derived Factor 1 
IL: Interleukin 
VEGF: Vascular Endothelial Growth Factor 
HGF: Hepatocyte Growth Factor 
EGF: Epidermal Growth Factor 
TGF-β: Transforming Growth Factor-β 
FGF2: Fibroblasts Growth Factor 2 
EPC: Epidermal Progenitor Cell 
TN-C: Tenascin-C 
MDSC: Myeloid-Derived Suppressor Cell 
 
  
NK: Natural Killer Cell 
DC: Dendritic Cell 
PGE2: Prostaglandin E2 
IDO: Indoleamine 2,3-Dioxygenase 
PD: Programmed Death 
CTL: Cytotoxic T lymphocytes 
Th: T helper 
IFN-γ: Interferon-γ 
M1: Classically activated Macrophage 
Treg: T regulatory cells 
M2: Alternatively activated Macrophage 
SOCS-1: Suppressor of Cytokine Signaling 
SHH: Sonic Hedgehog 
M-CSF: Macrophage-Colony Stimulating 
Factor 
TLR: Toll-Like Receptor 
TSP: Thrombospondin 
ELCAP: Early Lung Cancer Action Project 
IGRT: Image Guided Radiotherapy 
ICD: Immunogenic Cell Death 
DAMPs: Damage-Associated Molecular 
Patterns 
HMGB1: High-Mobility Group Protein-1 
CRT: Calreticulin 
HSP: Heat Shock Proteins 
VCAM-1: Vascular Cell Adhesion Molecule-1 











1.1 General principles on tumour immunology 
1.1.1 The immune system 
The immune system can protect us against infectious organisms and transformed cells, including 
tumour cells. It is broadly divided into two categories: innate immunity and adaptive immunity. 
Innate immunity comprises cellular, biochemical and physical structural protective mechanisms 
that provide the first line of defence against any infectious agents or transformed cells in a non-
specific manner. It includes the natural killer cells, macrophages, granulocytes, dendritic cells mast 
cells, cdT cells and natural killer T cells. While adaptive immunity provides a specific immunity and 
composed of T-lymphocytes, B-lymphocytes and their humoral mediators including cytokines and 
antibodies [1]. 
In the context of tumours, immunology portrays a relationship between the cells of the immune 
system with tumour cells. Tumour cells are mutationally corrupted, and their further development 
and progression depend upon the interaction between immune cell and tumours cells. Within 
cancer, the immune system acts in three different ways [1]. First, the immune system can defend 
the host against virus-induced tumours by suppressing or eliminating the viral infection. Second, 
the immune system can timely resolve the inflammation to hinder the development of 
inflammatory condition, which assists in tumorigenesis. Thirdly, the immune system can 
specificallly recognise and eliminate the tumour cells by interacting with tumour-specific antigens 
or the molecules induced by cellular stress (immunosurveillance).  
1.1.2 Cancer Immunoediting: from immunosurveillance to immune escape 
Paul Ehrlich first emphasised the significance of the immune system against tumours and this 
concept became formally presented as cancer immunosurveillance by Burnet and Thomas [2]. After 
that, there has been a significant number of studies observing the increased frequency of tumour 
in immune-deficient individuals, both in mice and humans [3]. Furthermore, people who were 
treated with immunosuppressive drugs following the transplantation and also HIV-positive 
individuals, demonstrate a high rate of tumour formation [4]. These observations collectively, 
confirms the idea of immunosurveillance. However, these concepts confronted a few restrictions 
because malignancy also happens in patients which have an effective immune system. Moreover, 
Prehn et al. endorsed that the immune system can indeed propel tumour development [5]. This dual 
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part of the immune system is explained through the concept of immunoediting by Robert Schreiber 
[3]. 
1.1.2.1 Three phases of cancer Immunoediting 
The immunoediting theory contains three 'Es.' The first "E" refers to elimination, which indicates 
the immunosurveillance capacity of the host immune system to eliminate tumour cells in incipient 
tumours (Figure 1.1) [3]. It can be called complete elimination when all the tumour cells are 
successfully eliminated, or incomplete when some of the tumour cells survive to the attack. 
According to immunoediting theory, incomplete elimination is a short-term of dynamic 
equilibrium between the immune system and developing a tumour.  
The second phase is called the equilibrium phase, in which the host immune system and tumour 
variant cells that have escaped from the first phase enter into a dynamic equilibrium (Figure 1.1). 
In that phase, the immune system exerts a continuous immunological pressure on tumours 
sufficient to limit their growth, but not entirely eliminate a tumour bed carrying many mutated 
cells. Albeit most of the primitive tumour cell variants are eliminated, new variations may emerge 
carrying different mutations that provide them with higher resistance to immune attack [3].  
Furthermore, the third E refers to escape and is the last step in which the immune system is unable 
to restrict tumour growth (Figure 1.1). Along these lines, tumour cells develop new strains which 
evade the immune system and keep on flourishing relentlessly (Figure 1.1)[3].  This capacity of 
tumour cells is considered as a 7th hallmark of cancer [6]. The third phase of the immunoediting 
process is also termed immunoevasion. Nowadays, much research is directed to comprehend the 
different process of immunoevasion for the advancement of better immune-therapeutic techniques 
to combat cancer [7]. 
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Figure 1.1: Three phases of cancer Immunoediting: Three phases of cancer immunoediting which 
may occur separately or collectively. One normal cell changed into cancer under multiple factors. First “E” explains 
the ctive role of immunity to protect against cancer. The second E represent the equilibrium state. The third E 
indicate Escape in which tumor adopt new variants which successfully evade the immune system and become 
clinically detectable. Adapted from Vesely et al Annual review of Immunology 29, 235-271 (2011).[8]  
 
1.1.3 Mechanism of Cancer Immune evasion 
1.1.3.1 Immunoselection of poorly immunogenic tumor cells 
As tumour progress, tumour cells continuously modified themselves at the genetic and epigenetic 
level to dodge the immune system. Furthermore, the immune system implies a continuous 
immunological pressure which facilitates the Darwinian selection of most suitable tumours strain 
to survive and multiply in the immunocompetent host and their offspring turn into the dominant 
population in atumour [9]. 
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1.1.3.2 Reduction of antigen presentation 
Tumour cells being innate in origin reflect self-antigens on their surface to which immune cells 
have tolerated during development [4]. However, due to the continuous mutational changes 
experienced by cancer cells after uncontrolled cell divisions, tumour-specific neoantigens may 
appear in tumour cells [10].  The immune system can identify them as a threat and mount a 
response against it [10]. However, tumour cells hide their identity, by changing its antigenicity, to 
avoid the surveillance of immune cells. This is one of the well-recognised and remote concepts in 
tumour immune evasion. One of the proposed strategies is promoter methylation to repress the 
expression of a specific tumour antigen-encoding genes [7]. As an alternative mechanism, tumour 
cells can shed their antigens temporarily by endocytosis or permanently into the circulation [3]. 
However, the down-regulation of MHC class I molecules in tumours, may alert NK cells, which 
are constantly screening the body’s tissues for cells which have lost the appropriate number of 
those receptors from their surface [11]. As an immune-evasive strategy, tumour avoid the attack 
by NK cells by repressing one of the six key MHC-I molecule [12]. On the other hand, some 
tumours utilized another route, by downregulating the antigen processing machinery especially 
MHC-I gene transcription [13](13). Sometimes, tumour cells also used the post-translational 
mechanism for repressing the necessary component of the MHC-I complex, for example, beta-2 
microglobulin and TAP protein, which has the essential role in antigen presentation (Figure 1.2) 
[14]. Deregulation of MHC-II molecule of antigen presenting cell is also observed, mostly the class-
II trans-activator or the different portion of MHC-II pathways like HLA-DM and HLA-DO are 
affected[14]. 
 
FFigure 1.2 This figure displays the 
involvement of heterodimer TAP1&2 and B-2 
macroglobulin wit MHC class 1 molecule in 
antigen presentation on cell surface. Failure of 
any Component preclude the antigen 
presentation. TAP-Transporter associated with 
antigen processing, MHC-Major 
histocompatibility complex. Adapted from 
Weinberg, R. A. The Biology of Cancer.  
(Gerald Science, 2013)[12] 
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1.1.3.3 Activation of anti-apoptotic mechanisms 
Tumour cells implied numerous strategies to avoid apoptosis, as it is one of the hallmarks of cancer 
[6]. For that purpose, tumour manipulate their biochemical profile, by increasing the level of anti-
apoptotic proteins (c-FLIP, Bcl-xL, Mcl-1) and cytokines (IL-4, IL-10, prostaglandin E2 and TGF-
b), in response to immune-induced cytotoxicity, hypoxia, loss of anchorage, etc [15, 16]. Tumour 
cells may also increase the expression of inhibitors of perforin/granzyme pathway to avoid CD8+ 
T-lymphocyte mediated cytotoxicity, as it was observed in a lung cancer study by Soriano et al [17]. 
As an evasive strategy, some type of cancer cell start producing a stress-related protein (MICA, 
MICB, ULBP4 and so on), around its surroundings as a trap. These proteins bind with NKGD2 
receptors on NK cells, which ultimately lead to endocytosis and degradation of NK cells [18]. One 
study in colon cancer indicated the release of DC3 receptor interact with Fas ligand to dodge the 
Fas-FasL induced apoptosis in immune cells [19]. 
Moreover, it has been observed that tumour cells may carry antibodies on their surface, and these 
antibodies carrying cells should lead to apoptosis by complement dependent cytotoxicity. However, 
cancer cells increase the magnitude of membrane-bound complementary regulatory proteins (m-
CRPs) (CD-46, CD-55, and CD-59) in their surroundings to evade it [20]. Tumour cells also 
decrease the expression of death receptor CD95 through deprivation or mutation of wild-type CD-
95 as in various cases of leukemias, hepatocellular tumours, and its related with the worst outcome 
[21]. 
1.1.3.4 Metabolic Reprogramming 
A significant proportion of tumour cells modify their metabolism to generate ATP from glycolysis 
instead of mitochondrial respiration, even in the presence of oxygen (Warburg effect) [22]. This 
modification of metabolism is critical to deal with the high energy need of the malignancy and for 
immune evasion as well. Regarding ATP production, tumour glycolysis prompt 18 times less ATP 
generation than oxidative phosphorylation [23]. Tumour cells preferred along these lines by 
increasing the rate of glycolysis up to 100 times [22] and used other biological molecules (NADPH, 
ribose five phosphates) for their expansions [23]. These metabolic changes may reshape the tumour 
microenvironment, as metabolic sub-products of glycolysis, such as, a lactic acid may create an 
acidic PH intratumorally which can be toxic to normal cells as shown in Figure 1.3. The elevated 
levels of lactate in the tumour microenvironment influence the efficiency and multiplication of T-
cells, NK-cells [24], maturation of dendritic cells [25], degranulation of perforin, and effectiveness 
of chemokine in tumour favour [26].  
 




Figure.1.3:Modification of cancer cell metabolism and immunoevasion. Tumour metabolize 
glucose to generate lactic acid by aerobic glycolysis which leads to acidic Ph n TME and contribute in the 
immunosuppressive environment. IDO leads to speed up the metabolism of tryptophan which ultimately favours T 
cell apoptosis. While high level of LXR @ in dendritic cell affect its maturation and immune role in the tumour. 
DC: Dendritic cell; IDO: Indoleamine 2,3-dioxygenase; MDSC: Myeloid-derived suppressor cell; TDO: 
Tryptophan 2,3-dioxygenase; TME: Tumour microenvironment. Retrieved and modified from  Bhstis et al 
Expert review of clinical immunology 10, 41-62 (2014).[27] 
 
The modified metabolism in tumour cells leads to the aggregation of indoleamine 2,3-dioxygenase 
(IDO), and tryptophan 2,3-dioxygenase (TDO), in amino acid (tryptophan) metabolism (Figure 
1.3). These provoke the inactivity of T-cell immune response, enrolment of T-reg cells and 
modulation of cytokine (TGF-b, IL-6, and IL-10), through GCN-2 (general control non-
depressible 2) stress kinase [28, 29]. 
Moreover, the modified metabolism and unlimited growth, lead to the condition of hypoxia in their 
microenvironment where hypoxia inducible component (HIF-a) expressed, which encourage the 
angiogenesis, and extension of immunosuppressive cells which assist in immunoevasion [30]. There 
is plenty of evidence in favour of that metabolic change which plays a significant role in developing 
an immunosuppressive environment, which ultimately supports immune evasion.   
1.1.3.5 Expression of co-regulatory receptors 
Tumour cell introduces numerous strategies to create a microenvironment in which the action of 
immune cells is compromised. There are several receptors present on immune cells which can 
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control the overreaction and self-attack. Many of these receptors, like CTLA-4, PD-1, ICOS 
(inducible T-cell co-stimulator), BTLA (B and T lymphocyte attenuator) and Fas death receptor 
are present on T-cells and show inhibitory control upon stimulation with the related ligand on 




Figure 1.4: Co-regulatory Receptors: It displays the interaction between the molecule of B7 superfamily 
molding TCR signaling. CD-28 and CTLA-4 communication with respective B7 ligand provide a negative signal 
upon T-lymphocyte enactment. ICOS bind with ICOS-L. PDL and PD interaction negatively regulates T&B 
cell activity (36). Retrieved and modified from Blank et al Cancer research 64, 1140-1145 (2004)[32] 
 
Tumour cell utilized these ligands to suppress the attack of tumour-specific T-cell and IL-10 and 
IFN-γ secretion. Beyond this, tumour cells also take control of that type of killing by getting the 
capacity of producing and directing the Fas ligand to the Fas death receptor displayed by numerous 
lymphocytes and killed them [19, 33]. In this way by killing immune cells, tumoruss keep up a safe 
zone for its growth. 
1.1.3.6 Recruitment of immunosuppressive Immune cells 
As another immunoevasive strategy, tumour cells promote the recruitment of immunosuppressive 
cells into tumors, such as regulatory T-lymphocytes (from 5 % to 30) or immunosuppressive 
myeloid cells[6]. Tumours release various cytokines (TGF-β), chemokines (CCL22, CCL28) and 
HIF-α that promotes the recruitment of T-regulatory cells as shown in Figure 1.5 [34]. 
 




Figure 1.5: T-reg cell and 
immunoevasion Regulatory T-cell and 
Tumour immune evasion. Tumour cells release 
the TGF-β and CCL22 chemokines, later binds 
the CCR4 chemokines receptor of the Treg and in 
this way, attracts them into the tumour. Treg cells 
have the inhibitory effect on cytotoxic and helper 
T-cells (12) Retrieved and modified from 
Weinberg, R. A. The Biology of Cancer. (Gerald 
Science, 2013)[12]. 
 
These T-regulatory lymphocytes can suppress and kill the helper T-cell and cytotoxic T-cell that 
recognise the same antigen as the T-regulatory cell and involve in T-cell tolerance [35]. In this way, 
by inhibiting the role of cytotoxic T cell and suppressing the action of helper T-cell, which can 
initiate the humoral and cellular immune response, T-regulatory cells assist in immunoevasion. 
Tumour cells also increase the myeloid-derived suppressive cells (MDSCs) as an immunoevasion 
approach. These cells facilitate a tumour immune evasion by employing the L-arginine (dependent 
& independent) procedure[36]. MDSCs secrete two enzymes, Arginase-1(AGR1) enzyme 
transform L-arginine into urea, and inducible nitric oxide synthase-2(iNOS2) converts L-arginine 
into nitric oxide (NO) and L-citrulline [37]. The elevated level of NO and superoxide ion induce 
the apoptosis of T-lymphocyte, while the production of peroxynitrites disturbs the peptide binding 
of T-lymphocyte and make them insensitive to antigen-specific immune stimuli [38, 39]. The L-
arginine independent procedure leads to CD-62L downmodulation, cysteine reduction, ROS and 
TGF-β production which hs a role in immunoevasion [40]. MDSc also secret VEGF, fibroblast 
growth factor, HIF-1, TGF-b and MMP-9 which may directly inhibit immune attack [41]. 
1.1.3.7 Development of mechanical barriers 
Tumour microenvironment (TME) consists of cells from endothelial, mesenchymal, and 
hematopoietic origin embedded in a complex extracellular matrix (ECM). These various 
components and their secretions play a vital role to suppress the immune network and assist in 
tumour growth. ECM (collagen, laminin, thrombospondin and fibronectin), have a role in 
immunoevasion by interfering with trafficking of immune cells [42]. Such as thrombospondin have 
a role in diminishing the T-lymphocyte efficacy by maintaining the dendritic cell (DC) in an 
immature state [43], and by suppressing IL-12 secretion in tumour microenvironment [44].  
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As an immune evasive strategy, tumour also increases the percentage of pro-tumour macrophages 
(TAM) and CAFs in their surroundings. In the following sections, It will be describe the role of 
CAFs and macrophages in tumour development.  
1.2 Cancer Associated Fibroblasts 
1.2.1 The heterogenic nature of CAFs 
Fibroblasts are one of the most abundant and multipurpose components of the tumour stroma, 
and their existence in higher amounts in a solid tumour is connected with poor prognosis [45]. It 
has been reported in many studies that tumour cells release various growth factors (TGF-β, PDGF, 
EGF, FGF) to recruit and activate tissue resident fibroblasts into the stroma [46, 47]. Several other 
local sources of CAFs have also been reported, like epithelial cells, endothelial cells, pericytes, 
adipose tissue, stellate cells, bone marrow cells which can differentiate into CAFs under the 
influence of tumour cells [48] (Figure 1.6).  









It has been reported in various studies that CAFs may originate from tumour cells by epithelial to 
mesenchymal trans-differentiation (EMT) [42]. However, this seems unlikely as CAFs are not 
tumorigenic themselves, and it is still debatable whether CAFs carry mutations in their genetic 
profile or not [49, 50]. The diverse sources of CAFs explain the heterogeneity of CAFs and make 
them hard to recognise from other mesenchymal cell types in TME (Figure 1.6). 
 
                                                                               
Figure 1.6: CAFs originate from 
different cell population via different 
mechanisms (55). Ziani et al,2018, 
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For their identification, CAFs express different markers that are lower or not expressed by normal 
fibroblast, such as α-smooth muscle actin (α-SMA), fibroblasts activation protein (FAP), fibroblast-
specific protein-1 (FSP-1), platelet-derived growth factor receptors (PDGFR), α/β, neuron-glial 
antigen-2 (NG2), periostin (POSTN), podoplanin (PDPN), tenascin-C (TNC), desmin, 
CD90/THY1, or discoidin domain- containing receptor 2 (DDR2)  [50, 51]. In the same way, 
Activated fibroblasts may not express all these markers simultaneously, probably showing the 
heterogenic nature of CAFs in TME´ and also their variable function in relation to TME [50, 51]. 
	
Figure.1.7:	Schematic description of normal fibroblast into CAFs. Tumour cells derived cytokines, chemokines 
and growth factors mediated paracrine trans-differentiation of resident fibroblasts into CAFs. There is an 
upregulation of Vimentin, α-SMA, FAP-1, FSP-1, Snail, CXCR4/ CXCL12, IL-33 and PDGFR surface 
markers and downregulation of CAV-1, PTEN and p21 in CAFs (Retrieved and modified from Utispan et al, 
59, 23-30 (2017).[52] 
 
1.2.1.1 Tissue Resident Fibroblasts versus CAFs 
Fibroblasts have been characterised by their typically spindle-shaped morphology, which is present 
in a quiescent state with minimal metabolic and transcriptional activity. In healthy tissue, fibroblasts 
keep homeostasis and integrity of the connective tissue by releasing the extracellular matrix 
proteins (ECM) like integrin, collagen and fibronectin [53]. Fibroblasts are also a source of matrix-
degrading proteases, such as (MMPs) which is critical for ECM remodelling [54]. In the case of 
wound healing or inflammation, fibroblasts become transformed into activated myofibroblast and 
increase the synthesis of ECM, producing chemokines, cytokines, enlisting immunocytes and 
applying mechanical forces to remodel the tissue structure [55]. 
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In tumour microenvironment, activated fibroblasts or CAFs attain a higher degree of contractile 
potential that is related with their ability to adjust the tissue architecture, obtains a proliferation and 
migration potential and turns out to be transcriptionally active to secrete various cytokines, 
chemokines and ECM proteins [56]. This capacity of fibroblasts to become activated was first 
recognised in wound healing [57] and along these lines in many pathological conditions, such as in 
acute or chronic inflammation[56]. Likewise, in the case of solid cancers, this tissue repair process 
would go on and never return to the steady state, which is why cancers are considered as “wounds 
that never heal”[58]. 
1.2.2 CAFs role in Tumour Progression 
Activated fibroblasts collected from human tumour stroma display specific characteristics 
compared to fibroblasts isolated from normal organs [59]. The capability of CAFs to assist in 
tumorigenesis is somehow dependent on their capability to prompt angiogenesis. CAFs release a 
high level of stromal-cell-derived factor-1 (SDF-1/CXCL12) and recruit bone-marrow-derived 
endothelial cells to assist in angiogenesis[60].  Numerous fibroblast activation ligands, such as 
TGF-β, bone morphogenic proteins (BMPs), platelet-derived growth factors (PDGFs), epidermal 
growth factors (EGFs), Fibroblast growth factors (FGFs) and sonic hedgehog (SHH) have a pro-
tumorigenic role (Figure 1.8). The elevation of heat shock factor 1 (HSF1) in CAFs enhances the 
HSF-1 a dependant tumour promoting mechanism in tumour cells, assisting a pro-tumour effect 
of the TME [61]. Similarly, Yes-associated protein-1 (YAP1) stimulation in CAFs increases ECM 
hardening and tumour cell infiltration [62]. De-regulation of p53 and Notch signalling pathways in 
CAFs assist their development [63]. CAFs secrete multiple matrix degrading protein (MMP-1, -3), 
which assist in motility and invasion of the tumour cell, as well as help in epithelial to mesenchymal 
transition (EMT) [64, 65].  
Additionally, fibroblast-derived exosomes also support tumorigenesis by regulating the fibroblast 
function, metabolic reprogramming and induction of cancer stem cell characteristics [64, 65]. ECM 
remodelling by fibroblasts can also contribute to the production and retention of cancer stem cell 
position. Fibroblast could be educated by cancer stem cells to prompt an environment that could 
support cancer stem cell retention. Cancer stem cells are a potent stimulator of fibroblasts by 
thrombospondin-2 (THBS2) manifestation, advancing malignancy in lung cancer[66]. Paracrine 
communication between cancer stem cells and fibroblast-derived insulin growth factor-II (IGF2) 
and IGF-1 receptor (IGF1R) signalling in cancer stem cells, prompting Nanog manifestation and 
stemness-like attributes in tumour cells [42]. 
 




Figures 1.8: The CAF assist cancer through angiogenesis, remodelling ECM and involve other secretions for 
their growth, survival and resistant therapy. The extracellular matrix (ECM), together with cellular components of 
the tumor microenvironment (TME), are actively remodelled and reprogrammed by cancer-associated fibroblasts 
(CAFs). ICAM1displayed on CAFs and served a s a site for immune cells functioning, while PDL1 &2 
involved in immunosuppression. (Intercellular adhesion molecule-1 ICAM1, programmed cell death protein 1 
ligand 1 (PDL1) retrieved and modified from Kalluri ER, et al, Nature Review Cancer (2016)[42]. 
 
1.2.2.1 CAFs role in Metastasis 
Metastasis is the ability of tumour cells to populate distant organs and establish a secondary tumour. 
In order to develop metastatic capabilities, tumour cells have to obtain motile features via EMT. 
In this way, tumour cells lose their cell-to-cell adherence and obtain a mesenchymal phenotype 
with an irregular mobile and migratory capability, allowing them to attack the encompassing stroma 
and ultimately intravasate the circulatory system.  
This procedure could be stimulated by CAFs via the production of HGF and GF-β [67]. CAFs 
could assist tumour cell invasion and proliferation by producing ECM-degrading MMPs. In this 
way, CAFs influence ECM density at the primary tumour site and may create pathways in the ECM 
to intensify the invasiveness of tumour cells[68]. This is the outcome of the release of matrix-
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associated growth factors, for example, VEGF, which, at the same time, induces tumor 
angiogenesis [69]. For example, one of the investigations demonstrated that CAFs liberated 
Tenascin-C (TN-C) [70] upregulate the NOTCH and WNT signalling pathway in tumour cells, 
which instigate cell migration and metastatic ability as displayed in Figure 1.8. TN-C also contributes 
in tumor angiogenesis [71]. In addition to the well-defined role of fibroblasts in metastasis by 
supporting EMT, it is also reported that CAFs can separate from a primary tumour along with 
malignant cells and enter into blood circulation to protect the cancer cells. Along these lines, CAFs 
also contribute to create an appropriate microenvironment at the secondary site [72]. Another 
investigation revealed that FSP-1 positive CAFs improve tumour metastasis by advancing an 
inflammatory environment [73]. All the referred documentation confirms the pro-invasive and pro-
metastatic function of CAFs and defines its role as a positive regulator of tumour growth and 
progression. 
1.2.3 CAFs role in antitumour immune response 
CAFs exert multiple immunomodulatory functions around tumours. CAFs can attain a secretory 
phenotype, facilitating the production of ECM protein, the manifestation of ECM remodelling 
enzyme and the secretion of plenty of cytokines and chemokines. A recent study supports the 
assumption that CAFs’ secretion may regulate the immune cell recruitment and function in tumour 
mass [42]. In this respect, CAFs can modify the anti-tumour immune response and facilitate 
tumour progression (Figure 1.8). However, these investigations are limited to in vitro studies only 
[42]. 
In general, CAFs are considered to provide an immunosuppressive TME [74]. In the hypoxic TME, 
CAFs, tumour cells, endothelial cells and immune cells actively interact with each other. This 
complex interaction intensify the complexity of their paracrine signalling responses. CAFs secretes  
various cytokines, chemokines and pro-angiogenic factors in settled tumours, containing inter alia  
IL-10, IL-8, IL-6, tumour necrosis factor (TNF), TGF-β, C-C motif chemokine ligand-2 (CCL2), 
CCL5, CXCL9, CXCL10, SDF1, HGF, prostaglandin E2 (PGE2), nitric oxide (NO), HGF and 
human leukocyte antigen-G (HLAG); these secretions may have direct or indirect effects on 




















Figures 1.9: CAFs immunomodulatory function in tumour. CAFs secrets various chemokines, cytokines and 
growth factors to reshape the TME and regulate both innate and adaptive immune cells and transform them to 
pro-tumour phenotype. Ziani et al,2018).Adapted  Frontiers in immunology 9, 414 (2018)[48]. 
 
 CAFs-derived IL-6 involved in the differentiation of monocyte towards macrophage instead of 
dendritic cells [76] and that CAFs-secreted cytokine also involve in the enlistment and activation 
of mast cells [42]. One of the in-vitro based studies showed that  CAFs derived IL-4, IL-6 and IL-8 
may stimulate the immunosuppressive myeloid cell differentiation [77]. CAFs secreted CXCL14 
involve in the macrophage recruitment towards a tumour [78]. All these studies mentioned the 
CAFs-immune cell interact with each other via paracrine signalling, which is very crucial for the 
proliferation and development of a tumour [79]. CAFs secreted CXCL9, CXCL10 and SDF1 
involve in the recruitment of T-cell [78]. CAFs-directed TGF-β can also modulate the function of 
T-cells by hindering the key genes involved in their cytotoxic activity (perforin, granzyme A and B, 
FAs ligand and IFN-γ)[80, 81] as well as cause the death of cytotoxic T-lymphocyte by suppressing 
the pro-survival protein Bcl-2 [82]. CAFs can also create an immunosuppressive TME via 
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generation of its metabolic reprogramming factors (IDO1, galectin, Arginase-2), that cause T-cell 
anergy and apoptosis [82-84]. Meanwhile, CAFs-directed TGF-β decreases the production of IFN-
γ by NK-cells, which is critical for priming the effector CD4+-TH1 cells to kill tumour cells [85, 
86]. Various investigations about melanoma, colorectal and hepatocellular carcinoma have 
demonstrated that CAFs-secreted PGE2/IDO can regulate the manifestation of NK-cell activating 
receptors, (NKp30, Nkp44 and NKGD2) as well as perforin and granzyme-B expression by NK 
cells, that can suppress the NK-cell cytotoxic action against tumour cells [87, 88]. In one of the 
subgroups of CAFs from lung cancer patietnts exhibited PDL-1 and PDL-2 on their surface and 
may involve in the T-cell suppression ex vivo [89]. CAFs also regulate the tumour immunity 
indirectly via its effect on tumour-angiogenesis [90]. CAFs and tumour cells also limit the activity 
of immune cells towards via constructing ECM-network. These ECM remodelling releases various 
pro-inflammatory cytokine, growth factors that can assist in immune cells collection  [91]. Along 
these lines, CAFs can regulate the immune cells around tumour cells to create an 
immunosuppressive TME. In the present study, we are also trying to investigate the 
immunoregulatory function of CAFs on monocyte-derived macrophages. 
1.3 Macrophages 
Macrophages are a functionally and phenotypically prominent populations of innate immune cells, 
which are crucial for tissue development and homeostasis [92]. They are available around every 
tissue and body organ that portrays a higher degree of heterogeneity and plasticity. Some 
populations of macrophages exist in numerous tissues, such as brain, lungs and liver. They are 
originated from the yolk sac or foetal liver during early development of the organism. In general, 
macrophages are recognized as bone marrow-derived cells of myeloid lineage that circulate in the 
blood as monocytes. In acute inflammatory condition, monocytes leave the bone marrow and 
circulate in the blood for one to two days. After that, these circulating monocytes enter the 
peripheral tissues, where they became transformed into macrophages[93]. 
Moreover, macrophages are an integral part of innate immunity, and they perform various 
functions. As a professional phagocyte, they are involved in the phagocytosis of microorganism 
and efferocytosis (phagocytosis of apoptotic cells). In this way, they constantly remove senescent 
cells, apoptotic cells and cellular debris from the body.  Macrophages are considered to be one of 
the major secretory cells in the body. The various cytokine, chemokine, and growth factors they 
produce influences tissue development and angiogenesis. Furthermore, they affect the remodelling 
of extracellular membrane content by releasing several metalloproteinases. Activated macrophages 
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are the primary source of toxic intermediates, such as reactive nitrogen species (RNS) and reactive 
oxygen species (ROS), involved in the antibacterial and cytotoxic functions. Their role as  antigen-
presenting cells involves displaying the antigen to T-helper cells and acting as a bridge between 
innate and adaptive immunity [94].  
1.3.1 Macrophage Polarization 
Macrophages are versatile cells, with the capacity to change their functional status according to the 
environment. They may perform immune effector roles in host defence and at the same time a 
homeostatic role to maintain the balance. This dual role of macrophages has been explained 
through a model (as portrayed in Figure1.10), which describes the macrophage activation as a 




Figure1.10: Linear classification of macrophages: Classically activated macrophages (M1) are at one end and 
alternatively activated macrophages (M2) at the other end. The gray area in between explians the wide of 
phenotypes that macrophages can adopt. Derived and modifies from Mosser,D.M and J.P.Edwards (2008)[95]. 
 
 In the background of the varying macrophages activation stages, a wide array of transcription 
factors, epigenetic factor and post-transcriptional regulators, are involved [96, 97]. In the 
perspective of the latest research and new development in immunology, some researchers argued 
that this polarisation of macrophages is oversimplified and there is a need to reassess this 
classification [93]. 
1.3.1.1 Classically Activated Macrophages (M1) 
The classically activated macrophages are the set of macrophages that is activated with pathogen-
associated molecular pattern molecules such as LPS, or endogenous/exogenous danger signals [98] 
or interferon –gamma (IFN-γ), to differentiate into an M1 phenotype. Interferon gamma is the 
primary signal that primes the macrophage towards the M1 phenotype [99]. LPS act through Toll-
like receptor (TLRs) 2 and 4 [94], which are manifested in high amounts in M1 macrophages. 
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Moreover, the M1 macrophage is the well-illustrated phenotype which can initiate the T-helper cell 
polarisation, into TH1 response. TH1 response is described by the generation of interferon–
gamma (IFN-γ), tumour necrosis factor (TNF- α), and Interleukin-2 (IL-2), which trigger the 
bactericidal activity of macrophage and prompt B-cell to make opsins and complement-fixing 
antibodies [94]. They act as professional phagocytic and antigen-presenting cells in the body. 
Metabolically in these macrophages, inducible nitric oxide (iNO) catalyzes the conversion of L-
arginine to NO and reactive oxygen species and is used as M1 marker [100]. In addition to the 
secretion of Th1 pro-inflammatory cytokines including IL-1, IL-6, IL-12, IL-23 and TNF-α. These 
macrophages have a strong cytotoxic capacity and anti-proliferative impact through the production 
of reactive oxygen species (ROS) and nitric oxide (NO) [96]. 
1.3.1.2 Alternatively- activated macrophages (M2) 
On the opposite, macrophages may be activated through TH2 cytokines (IL-4 and IL-13) [96] 
named as M2 macrophages. Several other factors like dexamethasone, IL-10, and transforming 
growth factor beta (TGF-b) also induce the M2 polarisation. Given their diversity, M2 
macrophages are further classified into other categories based on the nature of their stimulants- 




Figure 1.11: The 
polarization of 
monocyte into M1 
and M2 
macrophages and 
their function is 
described in this 
picture. Retrieved 
and modified from 




M2a phenotype is induced primarily through IL-4 or IL-13 stimulation. M2b phenotype is induced 
by immune complexes and Toll-like receptor ligands, or IL-1receptor antagonist (IL-1Ra). M2c 
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phenotype is triggered by IL-10, TGF-β1 or glucocorticoids, while M2d phenotype is initiated 
through Toll-like receptor and adenosine A2A agonist.  
The M2 macrophages are significant regulators of inflammation and wound healing [102]. They 
produce several growth factors like TGF-b and Platelet-derived growth factor (PDGF). These 
factors stimulate the proliferation of epithelial cells and fibroblast [103]. M2 macrophages also 
influence the expression of matrix metalloproteinases (MMPs) and tissue inhibitor metallo-
proteinases (TIMP) [103], which enhances the remodelling of tissues. They stimulate the 
angiogenesis through the release of a pro-angiogenic mediator like vascular endothelial growth 
factor (VEGFs) [104]. Moreover, M2 macrophages display a wide variety of scavenger receptors 
that mediate the endocytosis of macromolecules [105, 106]. Ligands of the scavenger receptor are 
present in the cell wall of gram-positive bacteria (nucleic acid, lipoteichoic acid, oxidised 
lipoprotein, sulphate polysaccharides and extracellular matrix components ECM) [107]. 
Metabolically, the M2 macrophage manifests high levels of arginase, which catalyses the conversion 
of arginine and water into ornithine and urea, it is therefore regarded as M2 marker.  
Recent research propose that different stimuli may induce different phenotypes in macrophages, 
[108] such as haemorrhage-associated macrophages (Mhem) which are induced by haemoglobin 
[109]. Mox macrophage is generated with oxidised phospholipids, and M4 macrophage produced 
by chemokine ligand-4 [109]. There is another category named as regulatory macrophages, 
portrayed by a FoxP+ expression, that has been reported among tumour-associated macrophages 
[108]. These macrophages have been claimed to participate in homeostasis by constraining the 
inflammatory immune response and prolonging the classical macrophage activation [109]. 
It is also speculated that regulatory macrophages are similar to M2 macrophages by constraining 
tissue damage. They are, however, not involved in wound healing [109]. 
1.3.2 Macrophages role in tumour progression 
TAMs are recruited into the tumour microenvironment under the influence of various chemokines 
( SDF-1, CCL-2) and growth factors (M-CSF, VEGF). Traditionally, macrophages were regarded 
as anti-tumorigenic (M1), repressing tumour growth, but TAMs show more frequently pro-
tumorigenic characteristics as portrayed in Figure 1.13. 
 




Figure 1.13: Role of TAMs in Tumor Development in tumor proliferalrtion and metastasis are described here. 
Retrieved and modified from Aras et el 2017 [110].  
 
TAMs are considered pivotal controllers of all phases of metastasis, and help the tumour cell in 
local invasions, intravasation into blood vessels, and extravasation to the peripheral tissue via 
various secretions such as matrix metalloproteinases, serine proteases, and cathepsins [111]. These 
secretions adjust the composition of the extracellular membrane by changing the cell-cell junction 
and advancing the basal membrane disruption, which assists in local invasion and tumour escape 
[112]. Mechanistically, the secretion of CSF-1(colony stimulating factor-1) by tumour cells triggers 
the TAMs to produce EGF (epidermal growth factor), which in turn facilitate the tumour cell 
migration and intravasation [113]. 
A current report manifested that, Warburg effect in TAMs propelled vascularisation, extravasation, 
and metastasis in the patient of adenocarcinoma. Blocking of glycolysis in TAMs with a suitable 
inhibitor disturbed this metastatic phenotype and turning off this observation of an increase in 
TAMs assisted angiogenesis, extravasation and epithelial-mesenchymal transition (EMT) [114].  
EMT assumes a fundamental part in tumour expansion and metastasis where polarised epithelial 
cells alter their appearance to mobile mesenchymal cells. The latest investigations demonstrate that 
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TAMs are important players of this process, which assists in the deprivation of cell to cell adherence 
and the acquisition of a mobile phenotype through the release of growth factors and cytokines 
(TGF-b, HGF, EGF, Notch, Wnt and NFkB) [115]. One of the studies explained that M2-
phenotype TAMs advanced the EMT in pancreatic cancer, partly via TLR4/IL-10 signalling 
pathway [110]. 
On the other hand, mesenchymal-like cancerous cells released granulocyte-macrophage colony 
stimulating factor (GM-CSF), which can polarise the surrounding macrophage into TAMs. TGF-
b secreted by the TAMs [116] or tumour cell under the stimulation of macrophage-derived cytokine 
(IL-6, IL-1 β and TNF-α) is another significant inducer of EMT in malignancy [117].  Multiple 
transcription factors are involved in TGF-b induced EMT such as Snail, ZEB, and bHLH families. 
TAMs are also the vital source of Matrix metalloproteinases, especially MMP-9. MMP-9 
contributes in EMT by disrupting tissue structure and creating space for a developing tumour. 
MMP9 can also liberate IGFs (Insulin-like growth factor), prominently IGF-1, which give survival 
signal to the cell, including cancer cells [118]. 
Furthermore, TAMs also stimulate the EphA4 through nuclear translocation of NF-κB. This is 
known to prompt the production of an active cytokines such as IL-16, IL-18 and GM-CSF, and 
along these lines keeps the stem cell-like attributes of cancerous cells and assist in EMT [119]. 
The progression of a tumour from benign to a malignant state depends on the expansion of 
vascularisation, known as angiogenesis, which supplies nutrient and oxygen to the cancer cells 
and enables them to proliferate, and metastasise. Due to its importance, angiogenesis is considered  
a hallmark in cancer [119]. TAMs released pro-angiogenic factor like VEGF, PDGF, TGF-b, and 
matrix metalloproteinases (MMPs) assist in neovascularization of tumours. It was documented that 
VEGF-A is involved in neo-angiogenesis and macrophage enlistment to the tumour site [120]. It 
propels the development of irregular vasculature in tumours, creating many branches with dead 
ends and leakiness that affect a tumour haemodynamic and drug distribution[121, 122]. The 
specific removal of VEGF-A in macrophages using lysozyme uncovered their contribution in the 
abnormal vasculature in tumours [123]. 
TAMs are engaged in immunosuppressive activity either by producing immunosuppressive factors 
such as prostaglandin, arginase-1, IL-10 and TGF-b. For example, TGF-b is a multipoint growth 
factor which advances the shift of M1 to M2 phenotype in TAMs. This, in turn, inhibits the 
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function of NK cells, the migration of dendritic cells and their antigen presenting capability [124, 
125]. Moreover, TGF-b, stimulates the helper T-cells (CD4+) towards the Th-2 response rather 
than Th-1 response and inhibits the cytotoxic T-cell (CD8+) activity [81]. 
Also, IL-10 (which is secreted by TAMs, cytotoxic T-lymphocyte and tumour cell) is an imperative 
mediator in the tumour microenvironment and plays an immunosuppressive and anti-
inflammatory role that favour the escape of a tumour from immune surveillance. IL-10 secretion 
by TAMs acts in an autocrine lope and represses the secretion of IL-12 [126]. Likewise, IL-10 also 
suppresses the expression of IFN-γ and dendritic cell maturation [127]. It also diminishes the 
antigen presenting ability of professional phagocytes about a tumour related antigen [128].   
TAMs also express COX-2, which leads to the immunosuppression and tumour progression [129], 
as COX-2 (cyclo-oxygenase 2) is involved in the conversion of arachidonic acid into prostaglandin 
endoperoxide (prostaglandin E2).  Macrophage also exhibits numerous ligands, PD-L1/PD-L2 
and CD80/CD86, which connect with lymphocyte inhibitory receptors as programmed cell death 
protein 1 (PD-1) and cytotoxic T-lymphocyte antigen (CTLA-4) respectively. The CAFs (cancer-
associated fibroblast) was also induced the aggregation of TAM.  The secretion of IL-10, TGF-b, 
and arginase in oral squamous cell carcinoma advances the immunosuppressive microenvironment 
by repressing the T-cell multiplication[130].  
Tumour-associated macrophages also suppress the effector T-cells function by recruiting the 
regulatory T-cells in their vicinity via CCL22 [81]. In vitro studies, these T-regulatory cells instigate 
the IL-6 and IL-10 expression by macrophages, prompting the autocrine upregulation of B7-H4 
and suppressive phenotype [127]. 
1.4 Impact of radiation in the tumour microenvironment  
Radiotherapy is applied to treat more than 50% of diagnosed cancer patients and accounts for up 
to 40% of total cures [131]. For a long time, the target of radiotherapy has been focused solely on 
the tumour cell itself, neglecting the surrounding microenvironment in which a tumour grows. In 
the recent past, new perspective of radiobiology emphasised the importance of TME. In the 
following chapter, I elaborate on how ionizing irradiation treatment affects the immune response 
of tumour cells and its related stroma. 
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1.4.1 Radiotherapy and tumor immunity 
The ionizing radiation can destroy tumours cell directly by damaging DNA through the generation 
of free radicals. This DNA damage prompts the production and presentation of tumour-associated 
neoantigen [132, 133] in addition to the secretion of cytokines from a tumour and stromal cells 
[134]. In this way, it can expose the tumour cell to the immune system by immunomodulation of 
cell surface molecules. Radiotherapy has been shown to enhance the expression of MHC class I 
molecule [135, 136] and NKG2D ligands [136] on the tumour cell surface, which increase the 
chance of recognition by antigen-specific CD8+ T-lymphocyte and NK cell. Radiotherapy can also 
trigger the manifestation of FAS death receptor on tumour cells, increasing the ability of FASL 
(ligand) bearing T-cells to recognize and destroy the tumour cells [137].  
All these proceedings can modify the immunosuppressive condition towards an immunoreactive 
microenvironment. Previously, it has been postulated that radiotherapy (RT) provide only 
immunosuppressive effects, because of the damage to tumour-infiltrating and the nearby immune 
cells, thus inducing lymphocytopenia [91, 138]. However, several documentations have shown that 
focal radiation may exert effects on distant tumour sites [139]. This radiation impact can be defined 
as an “abscopal effect” (off target). This abscopal impact can portray the radiotherapy as a pro-








Figure 1.14: Pro-immunogenic effect of radiation on tumour cells: Radiation therapy can induce the production of 
tumour antigen and make it visible to the immune system. After that, antigen presenting cells capture the tumour 
antigen and generate a specific immune response. This response is not limited to the primary tumour site, but it has 
an effect on distant tumour site (Abscopal effect). Adapted from Golden et al, 2012[140]. 
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Radiation can assist in cross-presentation of tumour antigens to T-lymphocyte through 
immunogenic cell death (ICD). ICD relates to the discharge of alarmins (danger signals) from 
tumour cells.  Alarmins are endogenous danger signals that bind to Toll-like receptors (TLR) and 
prompt the dendritic cell maturation and amplify the MHC-class I and MHC-class II cross-
presentation of tumour antigen to a tumour specific cytotoxic and helper T-lymphocyte 
appropriately. Following that, this activated T-lymphocyte come towards tumour mass and 
perform their effector function. Danger signals which interact with ICD incorporate the 
translocation of the protein, calreticulin (CRT), and liberation of high mobility group protein 1 
(HMGB1), adenosine triphosphate (ATP), and heat shock proteins (HSPs) 70 and 90 related with 
stress cells into the extracellular milieu [140].  
1.4.2 Effects of radiotherapy on TME components 
1.4.2.1 Effects on the Vasculature: 
Radiation leads to the destruction of endothelial cells, described by high permeability, separation 
from the basement membrane and apoptosis [141]. Apoptosis and the malfunctioning of vessels 
assist in fibrosis and post-irradiation inflammation. While inside vessels, irradiation induces a pro-
thrombotic condition featured by the accumulation of platelets, microthrombus formation, and 
enhances the adherence of inflammatory cells to endothelial cells [142]. Morphological changes 
may be reversible or irreversible depending on the dose of radiation, size-type-stage and location 
of a tumour, which ultimately influences the efficacy of radiotherapy [143]. Radiation-induced 
vascular damages enhance tumour hypoxia and instigate immune reactions via high production of 
chemokine/cytokine that stimulate the enrollment of immune cells. Following a tumour, 
revascularisation happens through hypoxia-inducible factor-1α (HIF-1α)-dependant and 
independent enrollment of bone marrow-derived cells (BMDCs) [142, 143].  
1.4.2.2 RT effects on the Stroma: 
Chronic inflammation is tightly related to fibrosis, in that consistent immune responses appears 
beside tissue remodelling and repair procedure.  In the normal tissue, invasion of inflammatory 
cells activates myofibroblast transformation, which results in the constant production of various 
growth factors, connective tissue growth factors,  angiogenic/ fibrogenic cytokines, chemokines 
that finally lead to the over deposition of extracellular matrix (ECM) [144]. The inflammatory 
reaction that originates quickly after radiotherapy is not identical to the one described, but shares 
some common features, such as, activation of stromal cells, self-sustaining signalling networks 
[145]. Cancer with a prominent desmoplastic reaction showed naturally radio-resistant phenotype, 
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as a result of integrin-mediated connection among tumour cells, stromal cell and surrounding ECM 
[146]. 
Radiotherapy of a tumour also affects CAFs, and CAFs from non-small cell lung cancer (NSCLC) 
specimens lose their tumor-invasive potential after high dose RT [147]. Moreover, many 
investigations mentioned CAFs as a radio-resistant cell, which can sustain radiation doses above 
50 Gy [148, 149]. Despite that, CAFs exposed to a single high dose of over 10 Gy of radiation 
develop a senescent phenotype due to irreversible DNA damage [121, 147]. These senescent 
fibroblast does not multiply, but they still produce various soluble factors to reshape the tumour 
microenvironment [150].  
1.4.2.3 RT effects on inflammation and the immune system: 
Radiotherapy always triggers an inflammatory response due to the instigated issue damage. 
However, after the initial proinflammatory phase, it starts the second phase in the context of tissue 
repair characterized by immunosuppressive activities, such as the recruitment of 
immunosuppresive cells and the release of immunosuppressive mediators [6]. After radiotherapy, 
the number of these immunosuppressive cells increase in the TME, as these cells are less 
radiosensitive than others lymphocytes [151]. These rise in the number of immune cells is counter-
balanced by the recruitment of new circulating immune cells and increase in antigen expression 
[152]. 
Radiation can have a direct and indirect effect via direct enrollment of immune cells such as 
intracellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), selectin and 
activation of inflammatory cytokine cascade (IL-1, TNF-α)[153]. All these events mainly 
interconnected via reactive oxygen species (ROS) and NF-κB , which cause cellular stress and 
death[153]. These events lead to the induction of an immune response via the production of the 
damage-associated molecular pattern (DAMPs) and their corresponding pattern recognition 
receptors (PPRs)[153]. 
In a nutshell, the complicated response of immune system to an irradiated TME is not fully 
immune-stimulatory or immune-suppressive. It depends on the balanced production of 
inflammatory cytokines, dendritic cell priming and antigen presentation, along with the expansion 
of the radioresistant population of macrophages and T-lymphocytes. The complex signalling from 
both tumour ICD and radiation-induced-modification to endothelial cells give rise to the invasion 
of immune cells which are more sensitive to immune-stimulation. Hence, radiotherapy is not an 
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ideal procedure for stimulating ICD of tumour cells followed by effective adaptive reaction. 
Nevertheless, some important events, like the modification of immunoregulatory cytokines, 
dendric cell maturation, T-cell recruitment and activation, can have a potential to stimulate the 
effective immune response against a tumour, if the immunosuppressive response can be 
suppressed. 
2 Aim of the study 
It has been extensively demonstrated that cancer-associated fibroblasts can act as a powerful 
immunoregulatory cell, with the ability to transform the anti-tumour features of immune cells 
towards pro-tumour features. Moreover, in the context of radiotherapy, some studies reveal that 
CAFs exposed to high dose ionizing radiation can experience a broad and permanent phenotypic 
modification. While, CAFs exposed to a lower dose fractioned radiotherapy, induce reversible 
DNA damage without growth arrest [147].  
On this background, in this thesis, we investigate the immunomodulatory features of primary CAFs 
on monocyte-derived macrophages in vitro, and explore if ionizing radiation, given at different 
regimens, is able to modify CAF-mediated immunoregulatory functions.  
The experimental settings comprise the use of both, co-culture of the two cell types and 
incubations with CAF conditioned media. Analyses of macrophage phenotype and functions 
include expression of cell surface co-stimulatory receptors, production of nitric oxide and secretion 
of inflammatory cytokines. 
 





3.2 Reagents for cell isolation and culture 
Bacterial-Collagenase C9407 Sigma-Aldrich USA 
Enzyme-Free Cell Dissociation soln. S-014-B Millipore USA 
Trypsin-EDTA T4049 Sigma-Aldrich USA 
Cell Freezing 
3.1 Cell Culture Medium and supplements 
Classical Media Catalog 
number 
Supplier Origin 
Dulbecco's Modified Eagle Medium 
(DMEM)  
D6046 Sigma-Aldrich USA 
DMEM/F-12 (1:1)    31330-038 Gibco UK 
Iscove’s Modified Dulbecco’s Medium 
(IMDM) 
BE12-722F Lonza Belgium 
Broncho-epithelial Growth Medium Kit CC-3170 Lonza Belgium 
 
Supplements 
Fetal Bovine Serum (FBS) S0115 Biochrome Germany 
Penicillin-Streptomycin P0781 Sigma-Aldrich USA 
Ascorbic acid                                                              CAS:50-81-7                 VWR Chemicals             Belgium 
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Axis Shield Norway 
Cell Washing    
Dulbecco's Phosphate Buffered Saline 
(PBS) 
RNBF9311 Sigma-Aldrich USA 





Plastic ware Catalogue 
number 
Supplier Origin 
96-Well plate white sterile plates 655073 Greiner Bio-One Germany 
Costar® Low attachment 24-well 
plates 
CLS3473 Sigma-Aldrich Netherlands 
FalconTMTissue culture 24-well 
plates 
353047 BD Falcon USA 
FalconTMTissue culture 6-well 
plates 
353046 BD Falcon USA 
NuncPetriDishes 249964 ThermoScientific USA 
NuncEasyFlask 25cm2 156367 ThermoScientific Denmark 
NuncEasyFlask 75cm2 156499 ThermoScientific Denmark 
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NuncEasyFlask 175cm2 159910 ThermoScientific Denmark 
Transwell cell culture inserts CLS3464 Sigma-Aldrich USA 
Cell Freezing 
Nunc CryoTube Vials 363401 ThermoScientific Denmark 
Other Supplies    
Centrifugal Concentrator  
(VIVASPIN 6) 
Vs0612 Startorius Stedim Germany 
Surgical blade P308 PARAGON UK 
Syringe 300613 BD plastipalTM Spain 
Syringe Filter Unit SLHA033SB EMDMillipore Ireland 
Nunc® inoculating loops I7773  Sigma-Aldrich USA 
 
 
3.4 Stains and dyes 
Name Catalog number Supplier Origin 
DAF-2DA 251505-1MG EMD Millipore USA 
 
3.5 Antibodies for flow cytometry 
mAntibodies Conjugate Catalog 
Number 
Supplier Dilution Origin 
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3.6 Recombinant Proteins 
Cytokines Catalog 
Number 
Supplier Reconstitution Origin 




1 mg/mL in dH2O with 
0.1 % BSA 
USA 
Recombinant Human IL-4 500-M04 
 
PeProTech 1 mg/mL in dH2O with 
0.1 % BSA 
USA 
Recombinant Human IL-10 200-10 PeProTech 1 mg/mL in dH2O with 






PeProTech 50 µg /mL in dH2O with 








ELISAs Kits Catalog 
Number 
Supplier Origin 
Human IL- 12 DuoSet® 
ELISA 
DY1240-05 R&D Systems USA 
Human IL-6 DuoSet® 
ELISA 
DY240-05 R&D Systems USA 
Human TNF-a DuoSet® 
ELISA 
DY210-05 R&D Systems USA 
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Human IL- 10 DuoSet® 
ELISA 
DY217B-05 R&D Systems USA 
 
3.8 ELISAs Reagents 





Reagent Diluent Concentrate 1 DY997 R&D Systems USA 
Color Reagent A and B DY999 R&D Systems USA 
Tween 20 P416 Sigma-Aldrich USA 
Sulphuric Acid (H2SO4) 95-95% 100731 Millipore Germany 
HEPES H3784 Sigma-Aldrich USA 
Sodium Hydroxide (NaOH) 
(FW = 40) 
71690 Sigma-Aldrich USA 
Wash Buffer (25x) WA126 R&D Systems USA 
Reagent Diluent Concentrate 2 DY995 Sigma-Aldrich USA 
Normal Goat Serum DY005 R&D Systems USA 
Tris (FW = 121.11) 72H5601 Sigma-Aldrich USA 
Sodium Chloride (FW = 58.44) K26478104917 MERCK Germany 
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FACSFlow 342003 BD Bioscience Netherlands 




352235 BD Bioscience USA 
 




MACS MultiStand 130-042-303 Miltenyl Biotec USA 
Separator 
MidiMACS Separator  130-042-302 Miltenyl Biotec USA 
Reagents 
CD14 Microbeads 130-045-101 Miltenyl Biotec USA 
Columns 
LS Columns 130-042-401 Miltenyl Biotec USA 
 
3.11  Instruments 
Bioluminescent image analyser Supplier Origin 
Image Quant LAS 4000 GE HealthCare Germany 
Centrifuges 
 
Page 39 of 102 
 
 
Heraeus Sepatech Biofuge 13 Heraeus Sepatech GmbH Germany 
Multifuge X3R ThermoScientific Germany 
Rotina 420R Hettich Germany 
Centrifugal Vacuum Concentrator 
(Rotavapor) 
Eppendorf /lifescience Germany 
Flow Cytometry 
FACSAriaTM BD Bioscience USA 
FACSCaliburTM  BD Bioscience USA 
Incubators 
37ºC Incubator Termaks AS Norway 
HERAcell 150i (CO2 cell culture 
incubator) 
ThermoScientific Germany 




Bio-Plex® 200 systems BIO-RAD USA 
EMax® Molecular Devices USA 
Luminometer Labsystems Luminoskan USA 
Multiskan Ascent ThermoElectronCorporation USA 
Microplate Washer 
Well Wash 4 MK 2 ThermoElectronCorporation USA 
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Filtration Vacuum manifold for bead 
washing 
Pall® Life Sciences USA 
Microscope 




3.12  Software 
Flow Cytometer Supplier Origin 
CellQuestTMPro Software BD Bioscience USA 
Flow Jo Office V7/8 Tree star USA 
FACSDiva Software BD Bioscience USA 
Microplate Readers 
Ascent Software® ThermoElectronCorporation USA 
Bio-Plex ManagerTM 6.0 
Software 
BIO-RAD USA 
SoftMax® Pro Software Molecular Devices USA 
Statistics Software 
Excel® 2018 Microsoft USA 
GraphPad Prism 7 GraphPad USA 
Image Soft Ware 
Spot Software 4.7 Diagnostic Instruments Inc. USA 
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4  Methods: 
Methods of the current study are explained in the following section. The flowchart presented in 
Figure 4.1 gives a general view of the method used and followed in our study. 
 
 
Figure 4.1: Flowchart of pathways followed in the Current study: Experimentation started by collecting tumour 
specimen and blood buffy coat from the University Hospital Northern Norway. Followed by the isolation, culture 
and irradiation of primary CAFs from non-small cell lung carcinoma (NSCLC). Monocytes (CD14+ cells) 
were isolated from human Peripheral Blood Mononuclear Cells (PBMCs) and differentiated into macrophages. 
Macrophages were incubated with irradiated and non-irradiated CAFs-CM or co-cultured with irradiated and 
non-irradiated CAF-cells. Immunomodulatory effects of CAF-CM and CAFs in co-cultures on uncommitted 
M0 and pro-inflammatory M1 macrophages were observed through surface marker expression (flowcytometry), 
Cytokine secretion (ELISA), and Nitric oxide production (flowcytometry). 
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4.1 Ethical Statement 
The Regional Committee for Medical and Health Research Ethics (REK-Nord) approved the use 
of human material for this study (Project-ID: 2009/895-4), and informed written consent was 
obtained from all patients. All methods involving human material were performed in accordance 
with relevant guidelines and regulations.  
4.2  Biological samples and Patients 
  Human lung tumour samples were collected from eight different patients diagnosed with NSCLC 
(Non-small cell lung carcinoma) at various stages and operated at the University Hospital of 
Northern Norway, Tromsø. Patients were not subjected to any additional therapy before sample 
collection. Furthermore, blood sample were collected from healthy blood donors attending the 
University Hospital of Northern-Norway Blood Bank. Information on patient demographics as 











Abbreviations: F: Female; M: Male N0: There is no spread to nearby lymph nodes; N1: The cancer has 
spread to lymph nodes within the lung and/or around the area. 
 
Table 4.1 Feature of the CAFs donor used for the current study  
Number Age Sex Tumor Type T-size 
(mm) 
T-stage  N-stage 
Donor 1 76 M Adenocarcinoma 60 mm 3 1 
Donor 2 71 M Squamous Cell carcinoma 35 mm 2a 0 
Donor 3 74 F Adenocarcinoma 35 mm 2a 0 
Donor 4 68 M Squamous Cell carcinoma 22 mm 1c 0 
Donor 5  71 F Adenocarcinoma 25 mm 1 0 
Donor 6 73 M Adenocarcinoma 26 mm 1c 0 
Donor 7 65 M Squamous Cell carcinoma 30 mm 3 0 
Donor 8 
 
78 F Squamous Cell carcinoma 18 mm 1b 0 
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4.3 Isolation and Culture of Primary NSCLC Fibroblasts 
General Procedure: 
Tumour specimens were collected from operated lung cancer patients (NSCLS).. Tumour tissue 
was collected in tubes containing ice-cold DMEM and immediately transported to the lab for 
further processing.  
A. Tissue digestion  
Tumour tissue samples were chopped into tiny pieces (1-1.5 mm3) in a petri dish with the use of 
surgical blades. These small pieces were collected into a T-25 cell culture flask and subjected to 
enzymatic digestion for 90 minutes with 0.8 mg/ml of bacterial collagenase in a final volume of 10 
ml DMEM/F-12 by putting the T-25 flask on a shaker in a standard incubator at 37 ºC. A 
continuous shaking was provided to the digested solution to liberate all possible cells, trapped in 
the small piece of tissues. After that, cells and undigested material were collected in a 50 mL of 
sterile tube and spun down at 350 x g for 7 minutes to remove the collagenase. Supernatant was 
discarded, and the pellet was resuspended in 24 ml of fresh growing medium containing DMEM 
supplemented with 1% penicillin streptomycin and 10 % Foetal Bovine Serum (FBS).These cell 
suspensions were poured into 6-well small tissue culture plate (2ml/well) and placed into the cell 
culture incubator at 37ºC with low oxygen (3 % O2) overnight, allowing all living and functional 
cells attach to the solid substrate.   
B. Cell purification and culture expansion 
After 2-3 weeks of incubation, the culture was a mix of fibroblasts and tumour cells.  In order to 
obtain pure fibroblasts cultures, wells were washed once with pre-warmed PBS followed by 10 min 
incubation in 2 mL of Enzyme-Free cell detachment solution at 37ºC. This step promotes the 
selective detachment of fibroblasts from the plate.  Then, the six-well plates were observed under 
the microscope to make sure fibroblast detachment. In case of poor detachment 500 µL of pre-
warmed Trypsin-EDTA (0.25 % - 1mM) solution was added to the wells for 1 minute.  
Enzyme-free solution detach the cells by keeping up the structural integrity of the cell surface 
protein, while Trypsin-EDTA detach the focal adhesion that are anchoring the cell to the flask. 
Detached cells were then collected in a 15 mL of tube, spun down at 350 x g for 7 minutes and 
resuspended in 10 ml of growth medium (DMEM +10% FBS). The cell suspension was divided 
into two T-75 cultural flask and 5mL of more growth medium were added into each flask. After 
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that flasks were placed for further propagation in a cell culture incubator at 37ºC in a 5 % CO2 
humidified atmosphere. 
C. Cell passage 
Fibroblasts culture were observed under the microscope after every 24 hours and the growth 
medium was changed with fresh medium every 2-3 days until they reached 80-90% confluency. 
Fibroblasts have elongated shape and are anchorage dependent, which means that they grow in a 
monolayer while attached to a solid or semisolid substrate.  
 
After attaining confluence, the medium was discarded, and the cells were detached using 5mL 
enzyme-free cell detachment solution for 5 minutes at 3% O2. The cell aggregation was prevented 
by adding 1 mL of Trypsin-EDTA (0.25 % - 1mM) solution in the last minute. After that cell 
solution was collected in a 15 mL tube, spun down, resuspended with 10 mL of growth medium, 
divided in two T-175 flasks with 15 mL final volume of complete DMEM medium and incubated 
at 37ºC in a 5 % CO2 humidified atmosphere.   
D. Cryopreservation of primary tumour fibroblasts  
After attaining the desired confluence (two passage), the cells were directly used for analysis or 
cryopreserved and used in later experiments. For cryopreservation, the cells were detached with 
enzyme free solution and Trypsin-EDTA (0.25 % - 1mM) solution as previously described, 
counted in a counting chamber, spun down and cryopreserved at 80ºC in freezing medium 
consisting of DMEM with 10% Dimethyl sulfoxide (DMSO) and 20 % FBS at 5x10^5 cells per 
mL per Cryotube.  
DMSO is one of the common cryo-protectant used in the laboratory to prevent the formation of 
ice crystals during the freezing process which can damage the cell membrane. But DMSO can be 
toxic for the cells at high concentration (> 10 %) or if the cells are exposed to DMSO for a longer 
Figure 4.2 Cancer Associated Fibroblast (CAFs) in culture in 
passage 1: cytoplasmic extension. Image was captured with 
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period.  That’s why, to get the best survival rate, the thawing of the cryopreserved cells was carried 
out as quickly as possible. Once the CryoTube was removed from the freezer, it was placed into a 
37ºC water bath until it was completely thawed. The cell suspension was then slowly added (drop 
by drop) in 10 mL pre-warmed complete medium. Cells were then seeded in a T-75 flask at 37ºC, 
in a 5 % CO2 humidified atmosphere and incubated for 24 hours for attachment, the next day the 
medium was replaced with fresh medium to completely remove the DMSO. 
4.4 Irradiation and preparation of Fibroblasts-Conditioned 
Medium 
Conditioned medium was collected from irradiated and non-irradiated cultured CAFs in order to 
examine fibroblast paracrine effects on macrophages. Both irradiated and non-irradiated cell 
cultures were processed in an identical conditions. 
General Procedure: 
During the 3rd passage, CAFs were seeded at 4 x 105 cells per T-75 flask and incubated for 24 
hours for attachment to the surface at 37ºC in a 5 % CO2 humidified atmosphere. After the initial 
cell attachment and desired confluence (60-70%), (ca. 2-3 days after seeding), the medium was 
removed and 6 mL of complete DMEM medium with 10 % FBS was added followed by irradiation. 
CAFs were irradiated with high - energy photons beam of 15 megavoltage produced by a Varian 
clinical linear-accelerator derived as a single dose of 18 Gy (1 x 18 Gy) or triple dose of 6 Gy (3 x 






Figure 4.3 Varian 
clinical linear-
accelerator. Image is 
showing the 24 well plates 
with cultured fibroblast. 
The gantry was positioned 
below the flask.  
 
In the fractionated regimen, there was a gap of 24 hours between subsequent radiations. For a 
beam produced by 15 MV the dose from photons to tissue is at its maximum at 30 mm depth. 
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Therefore T-75 flasks were placed in the centre of a 20 x 20 cm field size of 30 mm depth consisting 
of 3 water/tissue-equivalent Perspex-plates. Each tissue-equivalent plate was 10 mm depth (i.e., 30 
mm depth). The Gantry, which transports the beam from the linear-accelerator to the target, was 
positioned below the field (Figure 4.3). 
For the experimental groups that received a single radiation dose, fresh culture medium was 
replaced 3 days post-irradiation and collected 6 days post-irradiation in 15 mL tubes, centrifuge at 
2.200 x g for 5 min and passage through a 0.22-micron filter for elimination of potential 
contaminant cell bodies. CM was either used immediately for experimental analysis or frozen at – 
80ºC for further analysis in Eppendorf Protein LoBind tubes (1 mL/tube). Collected supernatants 
were normalized against number of cells in flaks. The cell density from the CM was at ~ 450.000 
cells/mL.Before analysis, CAF-CM was thawed and vortex for 30 seconds to ensure adequate 
mixing of the protein suspension. Supernatants from non-irradiated CAFs were also conditioned 
for 3-days at a density of ~ 450.000 cells/mL. Of importance, control cells were not allowed to 
reach over confluence before harvesting since cells could enter the senescence state. 
4.5 Isolation and Culture of Human Macrophages from Peripheral 
blood mononuclear cells (PBMCs). 
Bags of 50 mL containing fresh buffy coats from healthy donors were collected from the hospital, 
and PBMCs were isolated using a LymphoprepTM (Axis-Shield) density gradient centrifugation 
method. 
General principles: 
LymphoprepTM is a density gradient method through which cells were speared according to their 
density. The blood cells which have higher density than medium (1.077 g/mL) were sediment 
through the medium, for example red blood cells and polymorphonuclear cells, while the other 
cells such as mononuclear cells which have less density than this medium were retained in the 
interface by centrifugation. 
4.5.1 PBMC isolation procedure 
The blood buffy coat bag (50ml) were collected from UNN hospital which opened carefully with 
surgical blade and pour it into 75 cm2 culture flask. Blood was diluted 1:1 with 0.2% PBSA (bovine 
serum albumin in PBS) to make a final volume of 100 ml. 15 mL of LymphoprepTM solution were 
poured in 4x50mL tubes. Following that, we carefully added 25 ml of blood (blood + PBS) on top 
of 15 mL of LymphoprepTM e, through a proper care to avoid the mixing of blood and 
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LymphoprepTM solution. After that, centrifugation of all tubes were carried out at 800 x g, RT, 
without breaks (Acceleration:1 deceleration :1) for 30 minutes. Following that, the PBMC interface 
was collected with a Pasteur pipette, and washed three times with 40 ml of PBSA by centrifugation 
to eliminate the platelets. After last washing step, supernatants were discarded, and all cells were 
filtered through pre-separation filter in one tube. After counting, PBMC were divided into two 
fractions. One fraction was used for the isolation of monocytes (CD14+) cells and rest of PBMC 
were freeze down in a freezing medium containing 90 % FBS and 10 % DMSO. The cell density 
was 4x107 cell per cryotube (1ml/tube) and cryopreserved at – 80ºC.  
4.5.2 Immune-magnetic Monocyte Isolation 
Anti-CD14-coated microbeads were used for the positive selection of human monocytes from 
PBMCs by following the principle of magnetic activated cell sorting  separation(MACS ).  
The principle of the MACS separation is to isolate specific cell populations by particular surface 
antigens (CD molecules). In this process, samples are incubated with magnetic microbeads coated 
with monoclonal antibodies against a particular CD molecule. Then, the cell solution is loaded onto 
a MACS column which is placed in a strong magnetic field. Labelled cells with the magnetic 
microbeads are retained within the column while the unlabelled cells flow through. When the 
column is removed from the magnetic field, retained cells are eluted as the positively selected cell 
population. 
Procedure: 
The fraction of PBMCs selected for monocyte isolation were centrifuged at 300 x g for 10 minutes 
and re-suspended into 80 µL of MACS buffer (containing 0.2 % bovine serum albumin) per 107 
cells. After that, 20 µL CD14 microbeads were added, mixed well and incubated for 15 minutes in 
the refrigerator (4°C). Following incubation, cells were washed with 1-2 mL 0.2% PBSA buffer 
and centrifuge at 300 x g for 10 minutes. Supernatant were aspirated, and the cells again 
resuspended into 500 µL of buffer. After that, cells suspension was loaded onto a MACS-LS-
column inside the strong magnetic field. Following that, samples were rinsed with 3mL of 0.2% 
MACS buffer (0.2 % bovine serum albumin) onto the column. Then, we removed the column 
from the separator, and added 5mL of MACS buffer over it. We collected the magnetically labelled 
cells by firmly pushing the plunger into the column.  As a last step of monocyte isolation, the eluted 
cells were washed with cold MACS buffer and went for centrifugation at 300 x g for 10 minutes. 
The cell fraction was resuspended in the 10 mL of cell culture medium (RPMI-1640 culture 
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medium plus 10 % FBS plus 1 % penicillin-streptomycin) and no of monocytes were counted and 
analysed by flow cytometry.  (Labelling the antibody against CD14-FITC). 
4.5.3 Monocyte differentiation into Macrophages 
For the differentiation of monocytes (CD14+cells) into macrophages, a concrete amount of 
monocytes (6x106 monocyte) were re-suspended into 10 mL of cell culture medium (RPMI-1640 
culture medium plus 10 % FBS plus 1 % penicillin-streptomycin) and pour into medium sized petri 
dishes (83mm) at the concentration of 6x106 monocytes. The petri plates were put into the 
incubator for 30 minutes so that cells were attached to the surface of the petri plates. After that, 
macrophage colony stimulating factor mCSF (100 ng/mL) were added into the culture medium 
for the conversion of monocytes into macrophages called non-stimulated macrophages (MO-Mf 
phenotype). These monocytes were cultured for six days with a medium change after three days. 
At the sixth day, cells were harvested by using enzyme free solution (10 mL) and the small amount 
of Trypsin (500 mL). Cell scraper was used very gently to scrap the cells from petri plate. Than 
petri plate checked under the inverted light microscope to confirm the proper harvesting of 
macrophages (70% of the initial number of cultured monocytes) from the surface. It varied 
according to donor. 
After macrophages harvesting and counting, these macrophages (MO-Mf phenotype) were 
polarized by different stimuli for 48 hours. LPS (100ng/mL) and IFN-γ (20 ng/mL) were used for 
stimulation the M0 macrophages into M1 macrophages. While for polarization into M2 phenotype, 
the cocktail of IL-4 (50ng/mL) and TGF-ß (10 ng/mL) were used for 48 hours. 
4.6 Cell Surface markers expression by flow cytometry 
Cell surface markers represents proteins exclusively expressed on the surface of the cells and 
regularly used as markers of specific cell types. For the characterization of each phenotype of 
macrophages, a panel of various surface markers was used. These surface markers were specific 
for the particular phenotype of macrophages. For the detection of M0, M1 and M2 phenotype six 
different cell surface marker were used. HLADR, CD-40, CD-80 and CD8-6 markers were used 
for the characterization of M1 phenotype. While CD-206 and CD-163 were used as a marker of 
M2 phenotype. 
Procedure: 
For the characterization of macrophage phenotype, both stimulated and non-stimulated 
macrophages were collected in a 15 mL tube and counted. After that,  macrophages (400,000 cells) 
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were suspended into 500 µL of MACS buffer and the 10 µL of antibody was added to the 
suspension (according to manufacture protocol), mixed well and incubated for 15 minutes in the 
darkness at 4°C. After 15 minutes, the cells were washed by adding 1-2 mL of buffer and 
centrifuged at 300 × g for 10 minutes.  The pelleted cells were resuspended into 300 µL of MACS 
buffer and analysed by flow cytometry. PI were used to measure the live and dead cell ratio into 
the experiment.   
Flow cytometry: 
Flow cytomtery is a procedure applied to identify, count and measure the physical and chemical 
features of a population of cells/particles. The fundamental principle of flow cytomtry is the 
passage of cells in a single unit in front of a laser, so they can be identified and counted. The desired 
cells populations are fluorescently marked, and after that excited by the laser beam that emitted 
light at different length range. The transmitted light in the forward direction from the passing cells 
are typically used to identify the cell size, while the side scattered light provide detail about 
granularity and complexity. We used this procedure to identify and analyse surface markers 
expression in macrophages (CD-80, CD8-6, CD-40, HLADR, CD-206 and CD-163).  
The gating and cell identification methodology for our sample was as follows; cell doublets and 
clumps were eliminated by FSC-H vs. FSC-A. While FSC-A vs SSC-A were used to make gates 
and macrophage population were identified based on the expression of CD45+ cells. Data is 
analysed by a computer connected to the flow cytometry using a FACSDiva Software 
4.7 Co-culture of CAFs with Macrophages 
Co-cultured of Irradiated and non-irradiated CAFs from different donors with macrophages were 
carried out in order to study the immunoregulatory effects of CAFs on macrophages when the 
cells are in contact or close proximity. 
Procedure: 
Co-culture of CAF-cells into macrophages were divided into two part 
§ Isolation and culture of human macrophages 
§ Isolation, culture and irradiation of Cancer Associated Fibroblast 
The procedure for the isolation of human macrophages and CAFs cell were described above. 
After the step of monocyte differentiation into macrophages, and the preparation of irradiated and 
non-irradiated fibroblasts, cells were co-cultured in a 24 wells plate in triplicate manner. CAFs were 
used for co-culture experiments 24 hours after the last radiation cycle. Of importance, we also 
investigated the effect of low dose fractioned therapy (three multiple doses of 6-Gy radiation-
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3x6Gy) vs. single high dose radiotherapy (one single dose 18-Gy radiation-1x18Gy) on the cell 
surface marker of macrophage.  
In that experiment, four different CAFs donor were used for co-culturing with macrophages.  In 
each experiment, 400,000 macrophages/well were co-cultured for 48 hours with 200,000 
CAFs/well (both irradiated and non-irradiated) in a 1mL/well of culture media (RPMI-1640 
culture medium plus 10 % FBS plus 1 % penicillin-streptomycin). 
After 48 hours of co-culture of the macrophages and CAFs, the supernatant of the co-culture was 
collected from the each well. This supernatant was centrifuged at 4500 x g for 5 minutes and filtered 
from 0.2micron filter. This filtered supernatant was put into eppendorf tubes, marked well and 
keep it at -70°C, until analysis of the cytokine. 
Following the collection of supernatants, co-cultured cells were harvested for flow cytometry 
analysis as follows. Enzyme free solution (300 µL) were added into each well of the 24-well plate 
and incubate for 10 minutes. After that, 100 µL of Trypsin was added and incubated for 2-3 
minutes. After trypsin incubation, the cell scraper was used to scrap the cell gently. After cell 
scraping, the cells were collected into tubes and centrifuged at 300 x g for 10 minutes at 4°C. Cell 
pellets were dissolved in culture medium and stained for the different surface markers 
(Secction4.6). Labelled cells were analysed by flow cytometry, Fluorescent-Activated Cell Sorting 
(FACSCaliburTM).  
4.8 Incubation of Macrophages with CAF-CM 
To investigate the immunosuppressive effect of CAFs mediated by paracrine signalling, we 
collected 72 hour conditioned media from -irradiated and non-irradiated cultured CAFs and then 
incubated with macrophages for 48 hours. 
General Procedure: 
In that assay, we incubated the monocyte differentiated macrophages (M0, M1 and M2 phenotype) 
in triplicate in 24 well plate with the irradiated and non-irradiated CAF-CM for the period of 48 
hours. After the described time of incubation, supernatant and the macrophage cells were collected 
in the similar manner as described in the section 4.6. In that experiment, conditioned medium from 
five different CAF donors were used. In each experiment, 400,000 cells/well of Macrophage were 
incubated for 48 hours with 500 µL of CAF-CM of both irradiated and non-irradiated CAFs 
(450,000 cells/mL of CM). 
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The immunomodulatory effect of these irradiated and non-irradiated CAFs were studied through 
flow cytometry on the expression of macrophage surface markers (CD-80, CD-86, CD-40, CD-
206 and CD-163), (section 4.6). 
4.9 Nitric Oxide assay 
Nitric oxide is a small, unstable molecule which is produced by specific enzyme called nitric oxide 
synthetases (NOS). This enzyme has three isoforms. Two of the isoforms can generate Nitric oxide 
at the site of inflammation.  Endothelial nitric oxide synthetase (eNOS) is manifested in activated 
endothelial cells and generate NO, which can assist in vasorelaxation and vasodilation. Another 
isoform called Inducible nitric oxide synthetase, is mostly present in activated macrophages, 
wherein NO generation is critical for microbial cytotoxicity [154]. 
General Principal: 
DAF-2DA (4,5-diamino-fluorescein diacetate) is a non-fluorescent cell membrane permeable 
compound; once inside the cell, DAF-2DA is deacetylated by esterases resulting in the production 
of 4,5-diamino-fluorescein (DAF-2), which is retained within the cell. The reaction product of 
DAF-2 with Nitric oxide results in a benzotriazole derivative, a fluorescent compound which can 
be analysed by flow cytometry. 
General Procedure: 
The production of nitric oxide was measured in two different experimental settings: co-cultures 
and incubation with CAF-CM. 
Same procedure for harvesting the cells as mentioned earlier was adopted (section 4.6). After due 
timing (as described earlier), the cells were washed and resuspended in 500 µL of culture medium 
(RPMI1640 + 1 % penicillin-streptomycin, without appropriate FBS) containing 10 µM DAF-2 
DA (Calbiochem) / well.  The 24 well plate were incubated in an incubator at 37 ° C and 5% CO2 
for 1 hour. Soon after incubation, the cells were detached (as describes above) and analysed on the 
FACSAria Flow cytometry.  
4.10  Enzyme linked immunosorbent assays (ELISA) 
General principles: 
The sandwiched ELISA quantify antigenic protein between two layers of antibodies (i.e capture 
and detection antibody). The Capture antibodies of the ELISAs are attached to the flat surface of 
a 96well plate.  And the streptavidin that detects and binds to detector antibodies is conjugated by 
an enzyme (Horseradish Peroxidase (HRP) which is detected by a substrate Tetramethylbenzidine 
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(TMB). The enzyme – substrate compound turns the substrate into a coloured product. ELISA 
was specific for the detection of one protein at a time.  
 General procedure: 
Four different ELISAs were performed in this study to detect and measure the quantity of: IL-6, 
IL-12, TNF-α and IL-10. 
The concentrations of IL-6, IL-12, TNF-α and IL-10 were determined from the supernatant of 
non-irradiated and irradiated CAF with macrophages (incubated for 48 hours).  
The human TNF-α DuoSet® ELISA kit, human IL-6 DuoSet® ELISA kit, human IL-10 DuoSet® 
ELISA kit and human IL-12 DuoSet® ELISA kit was used in triplicates according to product 
protocol. But we need to repeat ELISA for some sample to adjust the dilution factor.  Samples 
were diluted 1:10 in reagent diluent for the determination of IL-6. Samples were diluted 1:5 in 
reagent diluent for the determination of TNF-α, while no dilution was made for IL-10 and IL-12.  
The reading of these plates was recorded through a microplate reader at wavelength of 450 nm. 
Ascent software were used for the recording of standard curve and for the estimation of unknown 
protein quantity in a sample. For curve fitting, again follow the product protocol.  
All the reagents and solution that were used in that experiment were purchases individually and 
reconstituted according to the instructions. Two-fold serial dilution were used for establishing the 
standard curve and it was run in duplicates for all the standard reagents for all the ELISA test. The 
experimental control was containing of M0, M1, and M2 macrophage. 
4.11 Statistical Analysis 
All results are the average determination of multiple donors with standard deviations (S.D) and 
displayed as fold M0-control. In ELISA assays only the readings above the detection limit of the 
assays are illustrated in the figures. Data were analysed using paired student’s t-test. The p value < 
0.05 were statistically significant. All statistics were analysed with Graph pad prism 7.00 for 
MacBook Air. Graphs were made using Microsoft Excel 2018 and Graph pad prism 7.00. 
 




5.1 Cancer-associated fibroblasts (CAFs) Isolation and Irradiation 
CAFs were isolated from non-small-cell lung carcinoma (NSCLC) tissue by enzymatic digestion 
and outgrowth, as described by Gorchs et al [155].  Under light microscope CAFs appeared elongated 
with spindle-shape morphology as illustrated in Figure-5.1. CAFs are anchorage-dependent and 
grow in a single layer. Culture expanded fibroblasts were checked for lineage specific markers 
including α-SMA and FAP-1 [156]. In this thesis, we have used CAFs collected from eight different 
donors.  Information on patient demographics as well as tumour stage, size and histologic subtype 
is summarized in table 4.1. 
Following initial platting, CAFs were culture expanded for 3 passages before experimentation. At 
the third passage (3-4 weeks), 70-80 % confluent cultures were irradiated by Varian Clinical linear-
accelerator. Figure 5.1 shows that irradiated cells acquired a flat and enlarged morphology which is 
indicative of induction of cell senescence and growth arrest.  In this study, immunomodulatory 
functions were compared between control CAFs and CAFs irradiated at single high dose (1x18Gy) 
or fractionated regimens (3x6Gy). 
Figure.5.1: CAFs isolation and irradiation: CAFs were isolated from NSCLC tumor samples, 
harvested and grown in the lab for 3 passages (70-80% confluency). CAFs were divided into three groups and 
irradiated by Varian clinical linear-accelerator. One group was irradiated once with a high dose (1x18 Gy) 
radiation and other group was irradiated with lower fractioned doses three-times 6Gy radiation given in three daily 
consecutive fractions.  
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5.2 Macrophage Isolation and Polarization 
Monocytes (CD14+) were isolated from PBMCs (Peripheral blood mononuclear cells) by the use 
of antibody-coated magnetic beads (MACS). Monocytes appeared circular in shape and attached 
loosely to plastic. These purified monocytes were incubated six days under the stimulus of M-CSF 
(100 ng/mL) to promote differentiation into macrophages, here referred to as M0-macrophages. 
After six days of incubation, uncommitted M0-macrophages appeared elongated in shape and 
firmly attached to the surface, under light microscope (Figure 5.2). These macrophages (M0) were 
then stimulated for 48 hours with LPS (100 ng/mL) and IFN-γ (20 ng/mL) for M1 phenotype or 
with IL-4 (50ng/ml) and TGF-ß (10 ng/mL) for the M2 phenotype. Following 48 hours of 
stimulation, M1 macrophage appeared more elongated in shape and M2 macrophage become more 
rounded and less adhesive as illustrated in Figure.5.2. 
 
Figure.5.2: Macrophage isolation and Polarization: Monocytes (CD14+) were isolated from PBMCs (Peripheral 
blood mononuclear cells). Isolated monocytes were incubated for 6 days with M-CSF to induce macrophage 
differentiation (Mo-phenotype). Monocyte-derived macrophages were further polarized into M1 and M2 macrophages 
by LPS+IFN-γ and IL-4+ TGF- ß respectively. 
To characterize macrophage subtypes, we analysed the surface expression of co-regulatory 
receptors of polarized macrophages. Surface expression of co-regulatory receptors normally 
overexpressed by M1 macrophages was determined by flow cytometry under different conditions. 
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Results in Figure 5.3 show that CD-40, CD-80, and CD-86 are overexpressed after stimulation with 
LPS and IFN-γ compared to unstimulated (M0) or IL-4+TGF-b stimulated cells (M2). 
Unexpectedly, expression of HLA-DR (MHC-II) became down-regulated by LPS and IFN-γ 
stimulation when compared to unstimulated macrophages. Because of this, we decided to exclude 













Figure.5.3:  Macrophage type-1 markers expression. The expression of CD80, CD86, 
CD40 and HLA-DR were analysed on stimulated and unstimulated monocyte-derived macrophages by flow 
cytometry. Macrophages were stimulated with LPS (100 ng/ml) and IFN-γ (20 ng/ml) for induction of M1 
phenotype and with IL-4 (50ng/ml) and TGF- ß (10 ng/ml) for induction of the M2 phenotype.  
 
Similarly, surface markers normally expressed by the M2 phenotype were determined after 
stimulation with a different cytokines mix. As shown in Figure 5.4, expression of the mannose 
receptor (CD-206) was elevated in resolution environment (IL-4 and TGF-b stimulation) as 
compare to M1 (Figure 5.4). However, this cytokine cocktail was not able to enhance the expression 
of the scavenger receptor (CD-163). Inverse results in the expression of CD-206 and CD-163 were 
observed by stimulation of M0 macrophages with the anti-inflammatory agent dexamethasone 
(results not shown).  
 















Figure.5.4 Macrophage M2 Cell Surface Marker: The expression of CD-206, and CD-163 
were analysed on monocytes-derived macrophages by flow cytometry. Macrophages (M0) were stimulated with LPS 
(100 ng/mL) and IFN-γ (20 ng/mL) to induce M1 phenotype and with IL-4 (50ng/mL) and TGF- ß (10 
ng/mL) to induce M2 phenotype.  
 
5.3 Effect of CAFs-CM on Macrophage Polarization 
We performed in vitro functional assays to investigate whether CAFs-CM (conditioned medium) 
exerts immune regulatory capabilities and has the power to affect the polarisation of macrophages.  
Conditioned medium collected from three randomly selected CAF donors exerted different, 
sometimes opposite, effects on the expression of M1 surface markers from both M1-stimulated 
and non-stimulated (M0) macrophages (Figure 5.5-5.7). While conditioned medium from donor 1 
(CAF-CM1) was able to potently induce the expression of the three co-stimulatory receptors on 
M0 macrophages, the conditioned medium from donors 2 and 3 were only able to enhance the 
expression of CD-40 (Figures 5.5-5.7) in non-stimulated conditions. On the contrary, conditioned 
medium from donor 3 (CAF-CM3) was able to down regulate the expression of the 3 surface 
receptors from stimulated (M1) macrophages (Figures 5.5-5.7), while the conditioned medium from 
donor 1 had a modest enhancing effect of the three receptors on M1 macrophages, and CM from 
donor 2 exerted down regulation CD-40 on stimulated macrophages. 
  
 




Figure.5.5: Effect of conditioned medium from 3 different CAF donors on the expression 
of CD-80 on macrophages. Monocyte-derived macrophages, non-stimulated (M0) and stimulated with LPS 
(100 ng/mL) and IFN-γ (20 ng/mL) for M1 phenotype were incubated with CAF-CM for 48 hours, and the 
expression of CD80 was analysed by flow cytometry.  White bars indicate expression levels in control macrophage 
cultures (M0 and M1). Results are expressed as fold M0 controls. 
 
Figure.5.6: Effect of conditioned medium from 3 different CAF donors on the expression 
of CD-86 on macrophages. Monocyte-derived macrophages, non-stimulated (M0) and stimulated with LPS 
(100 ng/mL) and IFN-γ (20 ng/mL) for M1 phenotype were incubated with CAF-CM for 48 hours, and the 
expression of CD-86 was analysed by flow cytometry.  White bars indicate expression levels in control macrophage 
cultures (M0 and M1). Results are expressed as fold M0 controls. 
  
 





Figure.5.7: Effect of conditioned medium from 3 different CAF donors on the expression 
of CD-40 on macrophages. Monocyte-derived macrophages, non-stimulated (M0) and stimulated with LPS 
(100 ng/mL) and IFN-γ (20 ng/mL) for M1 phenotype were incubated with CAF-CM for 48 hours, and the 
expression of CD-40 was analysed by flow cytometry.  White bars indicate expression levels in control macrophage 
cultures (M0 and M1). Results are expressed as fold M0 controls. 
 
In a similar manner, effect of CAF-CM on M2 surface markers expression was studied in non-
stimulated (M0) and stimulated (M1) conditions. Conditioned medium from the three randomly 
selected CAF donors were able to induce the expression of the M2 marker CD-206 on non-
stimulated macrophages (Figure 5.8). However, only conditioned medium from donor 3 (CAF-
CM3) was able to induce the same receptor on M1 stimulated macrophages (Figure 5.8). 
Moreover, conditioned medium from donors 1 and 3 were able to enhance the expression of CD-
163 on non-stimulated macrophages, while conditioned medium from donor 2 (CAF-CM2) was 
decreasing it (Figure5.9). Additionally, only conditioned medium from donor 3 (CAF-CM3) was 
able to induce a relevant enhancement of CD-163 expression if macrophages were stimulated with 
IFN-g and LPS. 
  
 




Figure.5.8: Effect of conditioned medium from 3 different CAF donors on the expression 
of CD-206 on macrophages. Monocyte-derived macrophages, non-stimulated (M0) and stimulated with LPS 
(100 ng/mL) and IFN-γ (20 ng/mL) for M1 phenotype were incubated with CAF-CM for 48 hours, and the 
expression of CD206 was analysed by flow cytometry.  White bars indicate expression levels in control macrophage 
cultures (M0 and M1). Results are expressed as fold M0 controls. 
  
Figure.5.9: Effect of conditioned medium from 3 different CAF donors on the expression 
of CD-163 on macrophages. Monocyte-derived macrophages, non-stimulated (M0) and stimulated with 
LPS (100 ng/mL) and IFN-γ (20 ng/mL) for M1 phenotype were incubated with CAF-CM for 48 hours, 
and the expression of CD-163 was analysed by flow cytometry.  White bars indicate expression levels in control 
macrophage cultures (M0 and M1). Results are expressed as fold M0 controls. 
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5.4 Differential effects of irradiated and non-irradiated CAF-CM 
on Macrophage polarization (Cell Surface Markers) 
 
To analyse the effects of ionizing radiation on CAFs-mediated regulation of macrophages 
polarisation, we incubated macrophages with CM from both irradiated and non-irradiated CAFs 
and determined the expression of specific M1 and M2 macrophage surface markers. Of 
importance, we also investigated the effect of low dose fractioned radiation (three multiple doses 
of 6 Gy radiation-3x6 Gy) vs. single high dose radiation (one single dose 18 Gy radiation-1x18 Gy) 
on the cell surface marker of macrophage. In each experiment, 400,000  macrophages/well were 
incubated for 48 hours with 500 µL of CAF-CM from both irradiated and non-irradiated CAFs 
(450,000 cells/mL of CM). Results are average determinations from five different CAFs donors. 
Neither irradiated nor non-irradiated CAF-CM was able to alter the expression of the co-
stimulatory receptor CD-86 in resting (M0) or LPS/ IFN-γ stimulated (M1) conditions (Figure 5.11). 
Very modest enhancing effects were observed on the expression of CD-80. Because of the very 
low intragroup variability, expression of CD-80 was statistically enhanced in uncommitted (M0) 
macrophages by all CAF-CM, but unchanged in stimulated (M1) macrophages (Figure 5.10).  
On the other hand, expression of CD-40 was moderately increased by all CAF-CM in M0 
macrophages, but it was statistically significant for both irradiated conditions only. No effects were 































Figure. 5.10: Effect of irradiated and non-irradiated CAF-CM on the expression of cell 
surface marker CD-80 on macrophage: White bars indicate expression levels in control macrophage 
cultures (M0 and M1). Results are expressed as fold M0 controls. Data represent the mean values of five different 
CAFs donor from triplicate determinations. Student’s T-test, p-value was determined between control and non-









Figure.5.11: Effect of irradiated and non-irradiated CAF-CM on the expression of cell 
surface marker CD-86 on macrophage: White bars indicate expression levels in control macrophage 
cultures (M0 and M1). Results are expressed as fold M0 controls. Data represent the mean values of five different 
CAFs donors from triplicate determinations. Student’s T-test, p-value was determined between control and non-
irradiated CAF-CM, control and both irradiated CAF-CM individually. (*p < 0.05). iCAF (irradiated 
CAFs). 
 






Figure.5.12: Effect of irradiated and non-irradiated CAF-CM on the expression of cell 
surface marker CD-40 on macrophage: White bars indicate expression levels in control macrophage 
cultures (M0 and M1). Results are expressed as fold M0 controls. Data represent the mean values of five different 
CAFs donors from triplicate determinations. Student’s T-test, p-value was determined between control and non-
irradiated CAF-CM, control and both irradiated CAF-CM individually. (*p < 0.05). iCAF (irradiated 
CAFs). 
 
Results in Figure 5.13 show effects of CAF-CM in the expression of CD-206 on macrophages. In 
non-stimulated conditions (M0), incubation with CAF-CM significantly increases the expression 
of CD-206 marker by both non-irradiated and irradiated conditions. On the contrary, in LPS and 
IFN-γ stimulated condition, the two irradiated CAF-CM slightly decrease the expression of CD-
206 markers expression. Figure 5.14 shows that expression of CD-163 increases to some extent 
after incubation of macrophages with irradiated and non-irradiated CAF-CM, even though 
differences are not significant. Similarly, in LPS and IFN-γ stimulated conditions, both irradiated 
CAF-CM slightly increase the expression of CD-163. No statistical differences were observed 
between the irradiated and non-irradiated CAF-CM. 
 
 











Figure. 5.13: Effect of irradiated and non-irradiated CAF-CM on the expression of cell 
surface marker CD-206 on macrophage: White bars indicate expression levels in control macrophage 
cultures (M0, M1 and M2). Results are expressed as fold M0 controls.  Data represent the mean values of five 
different CAFs donors from triplicate determinations. Student’s T-test, p-value was determined between control 





Figure. 5.14: Effect of irradiated and non-irradiated CAF-CM on the expression of cell 
surface marker CD-163 on macrophage: White bars indicate expression levels in control macrophage 
cultures (M0, M1 and M2). Results are expressed as fold M0 controls. Data represent the mean values of five 
different CAFs donors from triplicate determinations. Student’s T-test, p-value was determined between control 
and non-irradiated CAF-CM, control and both irradiated CAF-CM individually. (*p < 0.05). iCAF 
(irradiated CAFs). 
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5.5 Effect of CAF-CM on Macrophage-derived Nitric Oxide 
production 
To further investigate the paracrine effect of CAF-CM, we performed Nitric oxide assay by using 
the fluorescent probe diaminofluorescein diacetate (DAF-2DA). 
Outcomes of the control experiment is shown in Figure 5.15. Nitric oxide production (NO) was 
higher in pro-inflammatory conditions (LPS and IFN-γ stimulation). Inversely, in resolving 
conditions with TGF-β and IL-4, the production of NO is even lower than in non-stimulated 











Figure. 5.15: Nitric oxide production by stimulated and non-stimulated macrophages: 
Median fluorescence intensity by DAF-2DA for Monocyte-derived macrophages non-stimulated (M0), stimulated 
with LPS (100 ng/mL) and IFN-γ (20 ng/mL) for M1 phenotype and stimulated with IL-4 (50ng/mL) and 
TGF- β (10 ng/mL) for M2-phenotype was analysed by flowcytometry. Nitric oxide production was high in M1 
phenotype as compared to M0 and M2 states.  DAF-2DA (4,5-Diaminofluorescein diacetate). 
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Conditioned media from all CAF experimental groups could slightly increase the production of 
NO by uncommitted macrophages, although results were significant for 1x 18 Gy irradiated CAF-
CM only (Figure 5.16).  On the other hand, significant reduction in the production of nitric oxide 
was found in M1 stimulated macrophages upon incubation with both irradiated and non-irradiated 
CAF-CM. No differences were observed between the irradiated and non-irradiated CAF-CM. 
 
Figure. 5.16: Effect of irradiated and non-irradiated CAFs on the production of Nitric 
oxide in polarized macrophages by flow cytometry: White bars indicate expression levels in control 
macrophage cultures (M0, M1 and M2). Results are expressed as fold M0 controls. Data represent the mean 
values of three different CAFs donors from triplicate determinations. Student’s T-test, p-value was determined 
between control and non-irradiated CAF-CM, control and both irradiated CAF-CM individually. (****p < 
0.0001). DAF-2DA (4,5-Diaminofluorescein diacetate). iCAF (irradiated CAFs). 
 
5.6 Effect of CAFs-CM on Cytokine Expression by Macrophages 
As an alternative way to measure macrophage phenotype polarization, we proceeded to quantify 
pro-inflammatory and anti-inflammatory cytokines secreted to the media by macrophages, in the 
presence or absence of irradiated and non-irradiated CAFs-CM.  
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First we proceeded to check the expression of cytokines secreted by CAFs themselves. To 
reproduce the same experimental conditions, CAF cells were irradiated with single high-dose (1x18 
Gy and fractionated low dose (3x6 Gy) in a 24 well plate (0.2x106 CAFs/well) and incubated for 
48 hours at 37ºC in a 5 % CO2 humidified atmosphere. After that, supernatants were collected to 
quantify the pro-inflammatory (IL-6, IL-12 and TNF-a) and anti-inflammatory (IL-10) cytokines. 
Determination of human IL-6, TNF-α, IL-12, and IL-10 was done by specific ELISA immune 
assays. 
Figure 5.17 shown that CAFs secretes some amounts of IL-6 (300 pg/mL), while IL-12, IL-10 and 
TNF- α were not detected on CAFs supernatant. Values corresponding to CAF-derived IL-6 were 
substracted from the total values obtained on macrophage cultures. 
Figure. 5.17: Pro-inflammatory and anti-inflammatory cytokine secretion by CAFs, quantified by ELISA 
essay.  
 
Control experiment for expression of IL-6 by macrophages is shown in Figure 5.18. As expected, 
production of IL-6 is increased in pro-inflammatory conditions (LPS + IFN-γ) and decreased to 
baseline levels under resolving conditions (TGF-β + IL-4) 
 When incubated with CAF-CM, all CM were able to increase to a certain degree IL-6 production 
by both non-stimulated, and LPS/IFN-γ stimulated macrophages (Figure 5.19). In non-stimulated 
macrophages, the result was statistically significant only for low dose fractioned (3x6 Gy) radiation. 
On the contrary, in LPS and IFN-γ stimulated condition, it was significant only for the non-
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irradiated CAF-CM. No statistically significant differences were observed in both irradiated CAF-








Figure. 5.18: IL-6 production by monocyte-derived macrophages in different stimulatory 
conditions quantified by ELISA essay. Results only represent macrophage-derived IL-6 as CAF-









 Figure. 5.19: IL-6 produced by monocyte derived macrophages incubated with irradiated 
or non-irradiated CAF-CM were quantified by ELISA assay. Data represent the mean ±SD 
values from five independent experiments measured in duplicates. CAF-derived IL-6 was subtracted from full 
measurements. Results only represent macrophage-derived IL-6 as CAF-derived IL-6 were subtracted from full 
measurements. Student’s T-test, p-value was determined between control and non-irradiated CAF-CM, control 
and both irradiated CAF-CM. (**p < 0.001). iCAF=Irradiated CAFs. 
 
 
Page 68 of 102 
 
 
Similarly, Figure 5.20 shows the TNF-a production by macrophages in control experiments. TNF-
a  levels were high in the LPS and IFN-γ stimulated condition, while it was minimal in non-
stimulated and resolving condition with IL-4 and TGF-ß condition as expected. Of note, very low 
levels of TNF-a were measured in supernatants from irradiated and non-irradiated CAFs. 
Figure. 5.20:  TNF-a production by monocyte derived macrophages in different stimulatory conditions measured 
by ELISA assay.  
In experiments with CAF-CM, none of the experimental groups was able to modulate TNF- α 
expression by M0 macrophages, however, CM from both irradiated and non-irradiated CAF were 
able to decrease the production of TNF- α in M1 polarized macrophages. The result was statistically 
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Figure.5.21: TNF-α produced by monocyte derived macrophages incubated with 
irradiated or non-irradiated CAF-CM were quantified by ELISA assay. Data represent the 
mean ±SD values from five independent experiments measured in duplicates. Student’s T-test, p-value was 
determined between control and non-irradiated CAF-CM, control and both irradiated CAF-CM individually. 
(*p < 0.05). iCAF=Irradiated CAFs. 
 
IL-12 is another proinflammatory cytokines secreted by macrophages. In control experiments, we 
clearly observe high production of IL-12 in LPS and IFN-γ stimulated condition. While, the 
production of IL-12 was undetectable in non-stimulated or IL-4 and TGF-ß stimulated 
macrophages (Figure 5.22) displayed on next page. 
In CAF-CM experiments, we observe that CM from all experimental groups significantly block the 
















Figure.5.22: IL-12 production by monocyte derived macrophages in different stimulatory 









Figure.5.23: IL-12 cytokine produced by monocyte derived macrophages incubated with 
irradiated or non-irradiated CAF-CM were quantified by ELISA assay. Data represent the 
mean ±SD values from five independent experiments measured in duplicates. Student’s T-test, p-value was 
determined between control and non-irradiated CAF-CM, control and both irradiated CAF-CM individually. 
(****p < 0.0001).ND. Non-detected. iCAF=Irradiated CAFs. 
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Interleukin (IL)-10 is a recognized marker of M2 polarized macrophages [2] and supposed to be 
induced in the IL-4 and TGF-ß stimulated condition. Unexpectedly, the production of IL-10 was 
highest in the LPS+IFN-γ stimulated condition (Figure 5.24). Previous studies have also reported 
similar observations with IL-10 [157].  As internal control for the assay, we checked IL-10 
measurements in samples containing exogenously added recombinant IL-10 (result not shown). 
The latter experiments confirmed the correct functioning of the ELISA assay. 
The conditioned medium from all CAF experimental groups were able to trigger significantly high 
expression of IL-10 by uncommitted macrophages. On the other hand, both irradiated and non-
irradiated CAF-CM, slightly reduced the IL-10 production in M1-polrized macrophages. However, 
the result was significant only for non-irradiated CAF-CM. 
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Figure.5.25: IL-10 cytokine produced by monocyte derived macrophages incubated with 
irradiated or non-irradiated CAF-CM were quantified by ELISA assay. Data represent the mean 
±SD values from five independent experiments measured in duplicates. Student’s T-test, p-value was determined 
between control and non-irradiated CAF-CM, control and both irradiated CAF-CM. (**p < 0.001). 
iCAF=Irradiated CAFs. 
5.7 CAF-mediated effects on Macrophage cell surface markers 
during co-culture.  
To ascertain if CAFs could mediate additional or stronger effects on macrophages via direct cell-
cell interactions, we proceeded to measure effects in co-culture conditions. In each experiment, 
400,000 cells/well macrophages were co-cultured for 48 hours with 200,000 x106 cells/well of 
CAFs (both irradiated and non-irradiated). CAF cultures were used for co-culture experiments 24 
hours after the last radiation cycle. Macrophages from co-cultures with fibroblasts were positively 
selected by CD-45+ expression on flow cytometry as shown in Figure 5.26. 
 
 


















Fig. 5.26. Flow cytometry gate data. Macrophages from co-culture with fibroblasts were positive selected 
by CD-45+ expression (APC fluorochrome) and the fibroblast was mentioned as CD-45– population.   
 
CAFs in co-culture with uncommitted macrophages (M0) were able to induce a slight increase of 
CD-80 but had no effects on the expression of CD-86 or CD-40, with the exception of the 3x6 
Gy irradiated CAFs group which had an inductive effect on the expression of CD-40 (Figures 5.27-
5.29). Otherwise, no big differences were observed between irradiated and non-irradiated CAFs 
receptor regulation in any of the experimental groups. 
CAFs in co-cultures with M1-stimulated macrophages induced a slight decrease of CD-80 
expression and a significant decrease of CD-40 expression, while had no effects on CD-86 
















Figure.5.27: Effect of irradiated and non-irradiated CAFs on the expression of cell surface 
marker CD-80 on macrophages during co-culture: White bars indicate expression levels in control 
macrophage cultures (M0 and M1). Results are expressed as fold M0 controls. Data represent the mean values of 
four different CAFs donors from triplicate determinations. Student’s T-test, p-value was determined between 











Figure.5.28: Effect of irradiated and non-irradiated CAFs on the expression of cell surface 
marker CD-86 on macrophages during co-culture: White bars indicate expression levels in control 
macrophage cultures (M0 and M1). Results are expressed as fold M0 controls. Data represent the mean values of 
four different CAFs donors from triplicate determinations. Student’s T-test, p-value was determined between 
control and non-irradiated CAF, control and both irradiated CAF. (*p < 0.05). iCAF=Irradiated CAFs. 
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Figure.5.29: Effect of irradiated and non-irradiated CAFs on the expression of cell surface 
marker CD-40 on macrophages during co-culture: White bars indicate expression levels in control 
macrophage cultures (M0 and M1). Results are expressed as fold M0 controls. Data represent the mean values of 
four different CAFs donors from triplicate determinations. Student’s T-test, p-value was determined between 
control and non-irradiated CAF, control and both irradiated CAF individually. (**p < 0.001). 
iCAF=Irradiated CAFs. 
 
Non-irradiated CAFs induced a noticeable enhancement in the expression of both M2 markers 
CD-206 and CD-163 in uncommitted (M0) macrophages, however, this effect was to some extent 
blocked in the two irradiated CAFs groups (Figures 5.30-5.31). On the other hand, enhanced 
expression of both CD-206 and CD-163 on M1 stimulated macrophages was observed only when 
CAFs were irradiated at 3x6Gy (Figures 5.30-5.31). However, differences with controls were not 


















Figure.5.30: Effect of irradiated and non-irradiated CAFs on the expression of cell surface 
marker CD-206 on macrophages during co-cultures: White bars indicate expression levels in control 
macrophage cultures (M0 and M1). Results are expressed as fold M0 controls. Data represent the mean values of 
four different CAFs donors from triplicate determinations. Student’s T-test, p-value was determined between 









Figure.5.31: Effect of irradiated and non-irradiated CAFs on the expression of cell surface 
marker CD-163 on macrophages during co-culture: White bars indicate expression levels in control 
macrophage cultures (M0 and M1). Results are expressed as fold M0 controls. Data represent the mean values of 
four different CAFs donors from triplicate determinations. Student’s T-test, p-value was determined between 
control and non-irradiated CAF, control and both irradiated CAF individually. (*p < 0.05). iCAF=Irradiated 
CAFs. 
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5.8 Nitric Oxide production by Macrophages during co-cultures 
with CAFs 
In order to measure the immunomodulatory effect of CAFs on nitric oxide production by 
macrophages, monocyte-derived macrophages were seeded together with irradiated and non-
irradiated CAFs cells for 48 hours. Nitric oxide assay was performed by using fluorescent probe 
diaminofluorescein diacetate DAF-2DA as described earlier.  In control experiments, we 
demonstrated that pro-inflammatory conditions (LPS and IFN-γ stimulation) triggered an 
enhanced production of nitric oxide from macrophages. While its production was lower in non-
stimulated (M0) and resolving condition with TGF-β and IL-4 (M2) (Figure 5.15). 
CAFs from both irradiated and non-irradiated conditions statistically enhance nitric oxide 
production by M0-macrophages (Figure 5.32). On the opposite, all CAFs groups decreased the 
production of nitric oxide in the LPS- IFN-γ stimulated condition (M1-macrophagres). However, 
only the group of irradiated CAFs was able to decrease significantly the production of nitric oxide 
in M1-macrophages (Figure 5.32). 
Figure.5.32: Effect of irradiated and non-irradiated CAFs co-cultures on the production of Nitric oxide by 
polarized macrophages: Median fluorescence intensity DAF-2DA in Monocyte-derived macrophages non-
stimulated (M0), stimulated with LPS (100 ng/ml) and IFN-γ (20 ng/ml) for M1 phenotype, and stimulated 
with IL-4 (50ng/ml) and TGF- β (10 ng/ml) for M2-phenotype was analysed by flow cytometry. Stimulated 
and non-stimulated macrophages were co-cultured with irradiated and non-irradiated CAFs for 48 hours. Data 
represent the mean values of three different CAFs donors from triplicate determinations. Results are expressed as 
fold M0 controls. Student’s T-test, p-value was determined between control and non-irradiated CAF, control and 
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5.9 Effect of CAFs-Co-culture on Cytokines expression by 
Macrophages 
 
As we did with conditioned media, we checked the effects of irradiated and non-irradiated CAFs 
co-cultures on the production of IL-6, TNF-a, IL-12 and IL-10 from uncommitted (M0) and 
LPS/IFN-γ stimulated (M1) macrophages. As shown in Figure 5.33 control experiments showed 
elevated secretion of IL-6, IL-12 and TNF-a in LPS/IFNg stimulated conditions, and negligible 
amounts produced in un-stimulated or TGFb/IL-4 stimulated conditions. Unexpectedly, IL-10 




Figure.5.33: Cytokine production by monocyte derived macrophages in different stimulatory conditions, measured 
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In the case of non-stimulated macrophages, both irradiated and non-irradiated CAFs were able to 
enhance IL-6 production. However, results were significant only for the case of non-irradiated 
and fractionated regimen (3x6 Gy) CAFs. The irradiated group 1x18 Gy could also increase the 
production of IL-6, but it was not significant (Figure 5.34). 
On the other side, all CAFs groups increased the production of IL-6 in the LPS- IFN-γ stimulated 
condition (M1-macrophagres), although the result was significant only for single high dose 

















Figure. 5.34: Detection of IL-6 produced by monocyte derived macrophages co-cultured 
with irradiated or non-irradiated CAFs quantified by ELISA assay. CAF-derived IL-6 was 
subtracted from full measurements.  Data represent the mean ±SD values from four independent experiments 
measured in duplicates. Student’s T-test, p-value was determined between control and non-irradiated CAF, control 
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The production of TNF-a by uncommitted macrophages was negligible and unchanged after co-
cultures with irradiated or non-irradiated CAFs.  However, irradiated CAFs were able to induce a 
significant reduction of TNF-a secretion by M1 stimulated macrophages (Figure 5.35). 
Figure.5.35: Detection of TNF-α produced by monocyte derived macrophages co-
cultured with irradiated or non-irradiated CAFs measured by ELISA assay.  Data represent 
the mean ±SD values from four independent experiments measured in duplicates. Student’s T-test, p-value was 
determined between control and non-irradiated CAF, control and both irradiated CAF. (****p < 0.00001). 
iCAF=Irradiated CAFs. 
 
Interleukin (IL)-12 was undetectable in the media of uncommitted macrophages and this scenario 
persisted during co-culture with CAFs (Figure 5.36). However, both irradiated and non-irradiated 










Figure. 5.36: Detection of IL-12 produced by monocyte derived macrophages co-cultured 
with irradiated or non-irradiated CAFs measured by ELISA assay.  Data represent the mean 
±SD values from four independent experiments measured in duplicates. Student’s T-test, p-value was determined 
between control and non-irradiated CAF, control and both irradiated CAF. (****p < 0.00001). ND. Non-
detected. iCAF=Irradiated CAFs. 
 
Figure 5.37 describe the effect of both irradiated and non-irradiated CAFs on the production of IL-
10 by macrophages. The expression of IL-10 by uncommitted macrophages was enhanced after 
co-culture with all CAF groups, however results weren’t significant due to large intra-group 
variability. On the other hand, all CAFs group significantly reduced the production of IL-10 in M1 























Fig. 5.37. Detection of IL-10 produced by macrophages co-cultured with irradiated or 
non-irradiated CAFs. Expression of IL-10 were measured in the supernatants of both irradiated (iCAFs) 
and non-irradiated CAFs co-cultured with monocyte derived macrophages non-stimulated (M0), stimulated with 
LPS (100 ng/ml) and IFN-γ (20 ng/ml) for M1 phenotype, and stimulated with IL-4 (50ng/ml) and TGF-β 
(10 ng/ml) for M2-phenotype, for 48 hours by ELISA assay. Data represent the mean ±SD values from four 
independent experiments measured in duplicates. Student’s T-test, p-value was determined between control and 
non-irradiated CAF, control and both irradiated CAF. (**p < 0.001). iCAF=Irradiated CAFs. 
 
The following tables summarize all the results gathered in our study: 
Table 5.1   Cell Surface Marker Expression (M1-markers) 
Macrophages Experimental 
Settings 
CD80 CD86 CD40 
M0 Conditioned 
medium 
Slight increase by 
all CMs (Significant 




Increase by all CMs.  
(Significant  Value for 
irradiated CAF-CM) 
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3x6Gy group 
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but not significant 
Slight induction by ctr CAF 
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M1 Conditioned 
Medium 
No changes (slight 





induction by all groups 
No changes. Non significant 
enhancement by 3x6Gy 
 
Table 5.3   Nitric oxide production 
Macrophages Experimental 
Settings 
Nitric Oxide (NO) 
M0 Conditioned medium No changes (slight significant induction by 1x18Gy) 
Co-culture Strong significant induction by all groups 
M1 Conditioned Medium Significant inhibition by all CAF-CM 
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Co-culture Significant inhibition by all groups 
 




CAFs have been portrayed as an immunomodulatory cell to create a pro-tumour inflammatory 
environment [53]. Macrophages recognised as versatile cells with the capacity to change their 
physiology according to environmental stimuli [93]. Even though several approaches have been 
made to understand the interaction between these two a tumour stromal cells, the entire scenario 
still not clear. In the present study, we have investigated the immunoregulatory effects of CAFs 
affecting macrophage polarisation in vitro and the effect of ionizing radiation on CAFs 
immunoregulatory capabilities. The overall main outcomes of the present study are as follows: 
§ CAFs, both in co-culture and by conditioned medium, promote changes on uncommitted 
macrophages (M0) that harmonize with both M1 and M2 phenotypes. 
§ CAFs, both in co-culture and by conditioned medium, abrogate some of the pro-
inflammatory features of M1 macrophages as demonstrated by strong inhibition of nitric 
oxide production, strong inhibition of proinflammatory cytokines and a reduction of some 
M1 surface markers. 
§ Neither high dose radiotherapy (1x18 Gy) nor lower dose fractioned radiation (3x6 Gy) is 
affecting in general terms the immunoregulatory features exerted by CAFs over 
macrophages in vitro.  
In the present study, CAFs were collected from non-small-cell-lung-carcinoma (NSCLC) tissue by 
enzymatic digestion and outgrowth, as described by Gorchs et al [155]. Fibroblasts established as 
primary cell cultures, unlike immortalized cell lines, have a finite proliferative potential and closely 
mimic in vivo fibroblast features. In this way, the translation of in vitro data to in vivo effects in human 
can be done more precisely. On the contrary, fibroblasts established cell lines show altered 
phenotype with frequent genetic alterations, loss of p53 function, directing to infinite proliferative 
potential [158]. One constraint that can be experienced by operating with primary cell cultures is 
that original in vivo cell features can become altered after every passage. Therefore, to assure steady 
results, in our study, fibroblasts were used always after the third passage or cryopreserved to use in 
later experiments.  
Cell surface molecules are used as markers of cellular differentiation and function, imparting 
information into the phenotypic diversity, functional capability and activation status of the cells 
[159]. In our study, we used cell surface markers to categorise the polarisation status of 
macrophages. Surface expression of co-regulatory receptors (CD-80, CD-86 and CD-40) were 
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overexpressed in LPS + IFN-γ stimulated macrophages (M1) compared to unstimulated (M0) or 
IL-4 + TGF-b stimulated macrophages (M2). It is well documented that LPS + IFN-γ stimulated 
macrophages to display the high level of these co-regulatory receptors (CD-80, CD-86, CD-40), 
while alternatively activated macrophages (IL-4 stimulated) lack these co-regulatory receptors [160]. 
Moreover, the expression of mannose receptor (CD-206) was elevated in IL-4 + TGF-b stimulated 
macrophages while this cytokine cocktail was not able to enhance the expression of the scavenger 
receptor (CD-163). One previous finding describes that IL-4 strongly increase the expression and 
function of the macrophage mannose receptor (CD-206) [161]. On the contrary and similar to our 
observations, another study report that IL-4 + GM-CSF treated monocytes downregulate the 
expression of CD-163 [162]. Importantly, the opposite results in the expression of CD-206 and 
CD-163 were observed after stimulation of M0-macrophages with the anti-inflammatory agent 
dexamethasone [163]. This last observation and other recent studies in the field of immunology 
have highlighted the complexity and the oversimplified field of macrophages polarisation [164]. In-
fact, pro-inflammatory (M1) and anti-inflammatory (M2) macrophages portray two groups with 
overlapping cellular expressions [165]. The various stimulator of M2-polarization (IL-10, IL-4 or 
IL-13, glucocorticoid hormones, vitamin D3) induces different functional phenotypes in 
macrophages. According to their diversity, M2-macrophages are further classified into different 
categories based on the nature of their signal inducer-M2a (IL4 + IL1-3), M2b (IL-1receptor 
antagonist (IL-1Ra) + Toll-like receptor ligands), M2c (IL-10 + TGF--b) and M2d (toll-like 
receptor + adenosine A2A agonist) [101]. Along with these lines, the function of macrophage 
polarisation should be considered as a practically useful tool, a simple hypothetical framing to 
explain a continuum of diversified functional status. 
Previous studies speculated that CAFs can promote the polarization of macrophage towards M2 
phenotype [166]. In the present study was elucidated that monocyte-derived macrophages 
incubated with CAFs, up-regulated the expression CD-206 and CD-163 from non-stimulated- 
(M0), and LPS + IFN-γ stimulated suggesting that CAF promote the transformation of 
macrophages into pro-tumour phenotype of macrophages (M2).  Previous studies have suggested 
that CAFs-derived IL-6 and CCL2 promote the differentiation of macrophages towards M2 
phenotype [167]. One previous study validated that, the supernatant of CAFs preferably induce 
M2 phenotype, as CD-14mRNA level increased in human monocyte-derived macrophages [104]. 
On the other side, macrophages exposed to CAFs or their conditioned medium show a slightly 
enhanced expression of co-regulatory receptors (CD-80,  CD-40) in non-stimulated condition. This 
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slight increase in the level of M1- markers is actually the feature of M1-polarised macrophages. In 
this way, our study shows that CAFs function as an immunomodulatory cell modulating the 
macrophages polarisation in a way that resulting macrophages possess the characteristic of both 
M1 and M2 phenotypes. Besides this, many studies reported that polarisation of macrophages in a 
different type of a tumour seems more complicated, sometimes it showed more M2-phenotype 
with some feature of M1-gene expression[168, 169]. As most of the study describes that 
macrophages portray two groups of continua of overlapping cellular expressions [101, 170]. As 
one study described that macrophages marker expression and cytokine production in vitro is subject 
to the maturation and activation procedure [163].  Most of the macrophage-based studies used one 
or two markers to identify the polarisation status of the macrophage. In this way, it is very hard 
to assess the extent of overlapping of these markers on individual cells. As fully polarized M1 
and M2 (or alternatively activated) macrophages are the extremes of a continuum of functional 
states [171]. Considering the macrophage plastic nature [172], the use of cell surface markers to 
identify the polarisation of macrophages is a bit difficult. Cell markers alone don't completely 
characterise the various sub-populaces of macrophages [173]. There is a need for new 
nomenclature, that can relate the stimuli used for macrophage activation, must explain the 
macrophage nature [96]. In short, a more defined and powerful M1 vs M2 discriminating system 
is actually needed for better recognition and understanding of macrophage phenotype. 
On contrary, in LPS+ IFN-γ stimulated macrophages (M1), the expression of CD-80 and CD-40 
were down-regulated in CAF-educated cells, especially in co-culture conditions. These 
observations suggested that CAFs suppress the pro-inflammatory features of M1-macrophages by 
down-modulating the expression of co-regulatory receptors. These results clearly reflect the 
immunosuppressive potential of CAFs in fully polarised M1-macrophages. One investigation 
reported that isolated fibroblasts from lung cancer patients have been reported to manifest negative 
co-regulatory immune signals PDL1 and PDL2, that may have an immunosuppressive effect on 
T-cell activation [89]. We can extrapolate these reported observations and may speculate in co-
culture condition, CAFs may suppress the expression of co-regulatory receptors on fully polarised 
M1-macrophage in that way. There is further need to explore it. Many previous studies demonstrate 
that CAFs secrete CXCL12/SDF1, macrophage colony-stimulating factor (M-CSF), IL-6 and 
CCL2 to stimulate the recruitment of monocyte to TME and their polarisation towards M2-
phenotype[133, 174]. Importantly, the recent studies reported that collaboration of CAFs and M2-
macrophages is mutual, as M2-macrophage can also influence the phenotype of fibroblasts and 
change their reactivity [133, 174]. Previous reports revealed that M1 macrophages expressed CD-
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80 and CD-86, but a subgroup of M2-macrophages also displays CD-86 [175, 176]. Most 
surprisingly, CD-86 is the only receptor with unchanged expression in our study, as CD-86 co-
regulatory receptors are present on both M1 and subpopulation of M2-macrophages. This 
observation may suggest that CAFs does not modulate/regulate the expression of CD-86 by 
macroahages. 
Furthermore, in this study, we measured the nitric oxide (NO) production by macrophages. Nitric 
oxide production was high in pro-inflammatory conditions (LPS and IFN-γ stimulation). Inversely, 
in resolving conditions with TGF-β and IL-4, the production of NO is even lower than in non-
stimulated conditions. As it is generally accepted that in M1 macrophages, nitric oxide synthase 
(iNOS or NOS2) catalyse the conversion of arginine to NO and citrulline [154]. While M2 
macrophages catalyse this arginine into ornithine and urea via arginase-1 (Arg-1) [154]. According 
to previous observations, CAFs support the polarization of M2 macrophages, we hypothesized 
that CAFs-educated macrophages downmodulate the production of NO.  
The outcome of our studies displayed that CAFs significantly suppressed the secretion of NO in 
LPS + IFN-γ stimulated condition, while the production of NO was enhanced in non-stimulated 
macrophages (M0). This significant reduction of NO production in fully polarised M1-
macrophages showing that CAFs has the potential to suppress the features of M1-macrophages.  
On contrary, CAFs induces the expression of NO in un-committed macrophages. 
Based on our observations, we already suggest that these non-stimulated macrophages (M0) 
population has the potential to polarised both possible ways (M1 or M2). Similarly, CAFs educated 
macrophages have the characteristic of both M1 and M2 phenotype [177]. As CAFs induces the 
expression of CD-80, CD-40 and Nitric oxide in un-stimulated macrophages, which are the 
characteristic of M1-macrophages. In the recent past, Augsten et al showed that CAFs secreted 
chemokine (CXCL14) expression is specifically related to the nitric oxide synthase-1 activity 
(NOS1) [178]. This CXCL14-induced NOS1 feature of CAFs assumes an important role in tumour 
macrophage recruitment and tumour growth. Augsten et al identified NOS1 as an oxidative-stress 
induced competent of CAFs [178]. Here, we may suggest that CAFs-related NOS1 may have any 
role in this high production of NO  in non-stimulated macrophages. 
 
After describing the morphological feature and surface marker expression, we quantified the 
cytokine secretion to describe polarisation results. Determination of human IL-6, TNF-α, IL-12, 
and IL-10 was done by specific ELISA immune assays. The analysis of NO production was broadly 
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supported by the pattern of cytokine production. As expected, cytokine secretion of IL-6, TNF-α, 
and IL-12 was high in M1-stimulated macrophages, while they remained negligible in non-
stimulated (M0) and TGF-β + IL-4 stimulated macrophages (M2). Macrophage cytokine profile is 
the reflection of macrophage heterogeneity and plasticity. A number of cytokines have both 
positive and negative effect on tumour growth such as IL-6, IL-10 and TNF-α (214, 215). 
Macrophages are the major producer of inflammatory cytokines (IL-6, IL-12, TNF-α). The 
LPS+IFN-γ stimulated macrophages, produce pro-inflammatory cytokines (IL-6, IL-12, TNF-α), 
which initiate and maintain the inflammatory microenvironment. In the context of cancer, many 
studies explained the up-regulation of transcription factor NF-κB in macrophages by secretion 
from the necrotic tissues and high-mobility group protein 1 (HMGB1), matrix-degraded-proteins 
[179]. Moreover, in TME, macrophages are accumulated in the hypoxic area, where hypoxia 
induces a hypoxia-induced factor (HIF)-1 alpha-mediated transcriptionally programmed factor, 
which also activates the transcription factor NF-kB in macrophages [180]. The degraded 
proteolytic fragment of the extracellular membrane (ECM) such as the cryptic peptide of laminin-
10, can support the activation of inflammatory cells and induces the stimulation of inflammatory 
gene on macrophages through the activation of Toll-like receptor family members [181]. IL-12 has 
been showing to induce an antitumour immune response in numerous tumour model [182]. IL-12 
is produced by macrophage and dendritic cell stimulate the anti-inflammatory activities [183]. IL-
12 induces IFN-γ production by T-cell and NK cell, which improves the cytotoxicity by NK, NKT 
cells and cytotoxic-T-cells [183].  
The findings of our present study elaborated that CAFs clearly block the production of IL-12 and 
TNF-α in M1-polarised macrophages. These results may speculate that CAFs-secreted TGF-β, IL-
6, IL-10 can suppresses the function of macrophages and dendritic cells [86]. As CAFs-derived 
TGF-β is one of the prominent immunosuppressive cytokines in TME that can down-modulate 
the expression of MHC class II molecule and of co-stimulatory molecule CD-40, CD-86- CD-80, 
which are important for antigen presentation [86]. TGF-β also suppress the pro-inflammatory 
cytokines (TNF-α, IL-12 and IFN-γ) that stimulate T-cell recruitment and function [86]. A study 
elaborated that CAFs from hepatic carcinoma patient secrete CXCL12/SDF1 to attract monocyte-
derived precursor towards TME and convert them into MDSC (Myeloid-derived suppressor cells) 
via the IL-6-mediated STAT3 activation pathway [184]. In a similar way, another investigation 
described that pancreatic stellate cells (CAFs precursor) produced various cytokine (IL-6, VEGF, 
M-CSF) and chemokine (CXCL-12/SDF1, CCL2/MCP-1) to stimulate differentiation of 
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monocyte towards MDSCs in a STAT3 dependent manner[185]. All these investigations explained 
that CAFs have the potential to block the production of these pro-inflammatory cytokines. 
IL-6 is another pro-inflammatory cytokine. Our results elucidated that CAFs enhanced the 
production of IL-6 in non-stimulated (M0) and LPS + IFN-γ stimulated macrophages (M1). This 
observation validates that CAFs as an immunoregulatory cell, that can regulate the expression of 
cytokines. IL-6 is a pro-inflammatory cytokine, but CAFs stimulate the production of IL-6 in both 
populations. In addition to previously mentioned observations, ( slight induction of CD-80, CD-
40, induction of Nitric oxide), we can say that CAFs can promote the polarisation of non-
stimulated macrophages towards M1-phenotype. When we compare our results with other, it 
showed that IL-6 has a dual role in TME. Previously, the expression of IL-6 was believed to induce 
monocyte activation towards M1 phenotype [186, 187]. On contrary, many other studies 
considered IL-6 as a pro-tumorigenic cytokine, which is highly expressed in malignancy [188]. 
Another recent study showed that CAFs secreted IL-6 increase tumour proliferation by promoting 
M2-macrophage recruitment and development [189]. One recent study investigated that tumour 
growth and invasive capability were attenuated when IL-6 was blocked in bladder cancer [190].IL-
6 stimulates monocyte differentiation towards an M2 phenotype [189]. A previous study showed 
that co-culturing of fibroblast with bladder cancer cells (BCa) can assist in cancer cell invasion and 
IL-6 expression [177]. Our study also showed that CAFs upregulated the production of IL-6 in 
both polarised macrophages (MO and M1). These observations recommend that CAFs are capable 
to produce both pro-tumour and anti-tumour effect in the tumour [177]. 
 Surprisingly in our results, IL-10 (an anti-inflammatory cytokine) was up-regulated in M1, but not 
in M2 and M0 macrophages. IL-10 is a known marker of M2-macrophages, but the results of our 
study are similar to former results in murine and human models [162, 191]. Another study showed 
that LPS + IFN-γ + immune complex-stimulated macrophages produce a high level of IL-10 [94]. 
One of the studies claimed that TNF-α stimulates the secretion of IL-10 by resting and LPS-
stimulated macrophages as a counteractive mechanism to regulate the immune response [192]. 
Moreover, our results showed that CAFs as an immunosuppressive cell suppressed the production 
of IL-10 by M1-macrophages. On contrary, CAFs enhanced the production of IL-10 in non-
stimulated macrophages (M0). This enhancement of IL-10, with the addition to the previous 
finding of the present study (Induction of CD-206 and CD163), we speculate that CAFs can assist 
the polarisation of uncommitted macrophage towrads M2 phenotype.  
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These ambiguous results showed the higher plastic nature of macrophages, which can sense their 
microenvironment and modify their polarity [193]. Meanwhile, the present study clearly mentioned 
that CAFs promote bothM1 and M2 features from M0-macrophages. CAFs induce expression of 
CD-206, CD-163 and also IL-10 which are features of M2-macrophages. While, CAFs also induce 
the expression of CD-80, CD-40, IL-6 and nitric oxide (NO) which are features of M1-
macrophages. 
Radiation therapy has a profound effect on the tumour microenvironment. It can alter the tumour 
cell and their related stroma including CAFs [133]. In our study, we planned to analyse the effect 
of ionizing radiation on CAFs-mediated macrophage polarisation. Of importance, we compared 
the effects of fractioned radiation vs. single high dose radiation on the polarisation of macrophages. 
In co-culture settings, the CAFs treated with fractioned radiation, showed an enhanced expression 
of both CD-206 and CD-163 in LPS+ IFN-γ stimulated macrophages. However, differences with 
controls were not statistically significant due to prominent inter-donor heterogeneity. A previous 
study stated that a low dose of fractioned radiation produced a more activated fibroblast as 
compared to the higher dose [194]. In this way, the CAFs subjected to low dose fractioned radiation 
transform the M1-polarised macrophages towards M2 phenotype by enhancing the CD-206 and 
CD-163 expression. In an in vitro model of mammary stroma, high dose radiation per fraction was 
more successful in decreasing the pro-tumorigenic microenvironment through prevention of 
fibroblasts differentiation [194].  
Tumour immunity is interconnected by various soluble factors from immune cells and CAFs. Both 
immune cells and CAFs can have a tumour suppressing and promoting effects. CAFs produce 
various kind of soluble factors that play in a paracrine way to the tumour cell and their neighbour 
cells. CAFs generated various immunosuppressive molecules such as TGF-β1 [195], PGE2, IDO 
[196], CXCL-12/SDF1 [184], CCL2/MCP-1 or tenascin-C [185]. All of these molecules are 
involved in the immunosuppressive action of CAFs. One of the studies illustrated that CAFs 
supernatant contained IL-4, PGE2 and TGF-β cytokines; but the production of these cytokines 
not varied after exposure to a radiation dose of 18-Gy [155].  In the present study, all our results 
displayed that CAFs-mediated effect on the macrophage polarisation are identical for both 
irradiated and non-irradiated CAFs, and unrelated with the fractionation procedure and radiation 
dose. Previous investigations have mentioned CAFs as a radio-resistant cell which can sustain a 
high dose of radiation above 50 Gy [148, 149]. Despite that, CAFs exposed to a single high dose 
of over 10 Gy of radiation develop a senescent phenotype due to irreversible DNA damage [147]. 
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These senescent fibroblast does not multiply, but they still produce various soluble factors to 
reshape the tumour microenvironment [150, 197]. In a similar way, Hellevik et al showed a High 
dose of radiation can increase the MMP3 and decrease the MMP1 expression, but it had no effect 
on the manifestation of other major MMPs [147]. In this way, high dose of the radiation applied 
the favourable inhibitory effect on the proliferative, migratory and the invasive ability of lung CAFs 
[147]. The present study manifested that CAF-mediated effects over macrophages are induced by 
paracrine signals because similar results were observed via a conditioned medium as well co-culture.  
7 Conclusions and future directions 
In this project, we demonstrate the presence of a cellular cross-talk between human freshly isolated 
CAFs from non-small-cell-lung-carcinoma (NSCLC) tissue and human freshly isolated 
macrophages from peripheral blood of healthy donors. 
Few primary observations can be featured from this study; 
§ CAFs both in co-culture and by conditioned medium, promote changes on un-committed 
macrophages (M0) that harmonize with both M1 and M2 phenotypes. 
§ CAFs, both in co-culture and by conditioned medium, abrogate some of the pro-
inflammatory features of M1 macrophages as demonstrated by strong inhibition of nitric 
oxide production, strong inhibition of proinflammatory cytokines and a reduction of some 
M1 surface markers. 
§ Neither high dose radiotherapy (1x18 Gy) nor low dose fractioned radiation (3x6 Gy) is 
affecting in general terms the immunoregulatory features exerted by CAFs over 
macrophages in vitro. 
 
The immune system plays crucial roles in cancer development. On one side, tumour modifies itself 
at the molecular, metabolic and genetic level to gain resistant against apoptosis. On the other side, 
tumour cells evade the immune system by adjusting their immunogenic profile and expanding the 
immunomodulatory cells and immune-suppressive mediators. Plenty of work has been carried out 
for the understanding of the molecular pathway in the cancer cell, followed by the development of 
therapeutic strategies to cure cancer. However, researchers are confronted with tremendous 
challenges in this attempt such as tumour cells genomic instability, that is responsible for the 
ultimate attainment of a drug-resistant phenotype. The better understanding of the interaction 
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between tumour cells and stromal cells and their contribution for tumour initiation and 
proliferation may give us new opportunities to invent novel treatments, with the objective of 
targeting the genetically stable stromal cells or their paracrine factors, and in this manner prevail 
the drug resistance and limited the tumour development.    
Nowadays, the role of CAFs in tumour formation and proliferation via its chemokine and cytokine 
secretions are generally accepted. Therefore, in the last few years, CAFs have been chosen as a 
potential therapeutic target in tumour-immune therapy. Hence, in order to develop more useful 
and practical therapeutic strategy against CAFs or CAFs paracrine secretions, advanced 
translational research on CAFs-tumour cells and CAFs-tumour stromal cells interaction are 
required.  
It is important to indicate that CAFs incorporates the heterogeneous population of cells and the 
extent of heterogeneity in CAFs subtype can differ among the tumour type, tumour stage and 
tumour position in the body [198]. Along these lines, there are over 100 types of a tumour 
containing different CAFs subtypes and CAFs-paracrine factors, that may fluctuate considerably 
among tumour type. Furthermore, other features like the settlement of hypoxic condition in rapidly 
proliferating tumours may increase the production of cytokines and chemokine which is not 
present in high vascularized tumours. Meanwhile, our current study addressed the 
immunoregulatory potential of CAFs and their effect on macrophages polarisation. 
In the future prospect, we can extend our study by working in various directions:  
§ Further study about CAFs potential for macrophage repolarization 
§ Continue to investigate CAFs-derived soluble factors accountable for immunosuppressive 
effects. 
§  Comparison of the secretory profile of normal lung-fibroblast isolated from non-
cancerous tissue vs NSCLC-Associated fibroblast. 
§ Study the effect of CAFs on other cell types of immune system such as neutrophils, Natural 
killer cells, dendritic cells, T-reg cells. 
§ Study the potential connection of CAFs with infiltration of immune cells (Macrophages, 
NK-cells, MDSc, T-reg cells, Th2 and Th17) in lung tissue of NSCLC mice/patient.  
 Study the immunoregulatory potential of CAFs in animal models. 
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